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SUMMARY 
 
The current strategy for the prevention of cardiovascular diseases (CVD) is to stratify 
patients at risk for CVD using different algorithms. However, this has resulted in a high false-
positive rate, for example, of 68% and 86% for high and intermediate CVD risks, 
respectively, in the Munster Heart Study (PROCAM). Novel biomarkers are hence needed to 
improve the reliability and the cost-benefit relationship of preventative measures. Since a 
biomarker should ideally be an indicator of normal and pathogenic processes as well as 
pharmacologic responses to a therapeutic intervention, the potential candidate new markers 
are those that are relevant to the pathophysiology of atherosclerosis. Several candidates have 
emerged, for example 27-hydroxycholesterol (27OHC), sphingosine-1-phosphate (S1P), 
sphingolipids and phospholipids. 
Research over the last decade has revealed that HDL plays a pivotal role in the 
pathophysiology of atherosclerosis, mainly due to its role in removing the excess of 
cholesterol in peripheral cells via a reverse cholesterol transport pathway. However, HDL also 
displays pleiotropic effects on the cardiovascular system which are independent of the reverse 
cholesterol transport mechanism. 27OHC and S1P are of potential interest due to their roles in 
HDL metabolism and function. 
Published LC-MS methods for the analysis of 27OHC still lacked sensitivity for the 
measurement in animal models (single mouse) and lipoprotein fractions. Due to this reason, 
an LC-MS method using atmospheric pressure photoionization (APPI) has been developed 
and validated. The method was more sensitive than the published LC-APCI-MS or GC-MS 
methods, enabling us to analyse as little as 15 L sample volume with a lower limit of 
quantification (LLOQ) of 40 ng/mL or 4.9 pmol on column. 
Subsequently, the role of 27OHC in relation to cholesterol metabolism was evaluated 
for the first time in patients with monogenic disorders affecting HDL metabolism. In most 
cases, the defects in HDL metabolism affected the 27OHC concentrations in HDL in a similar 
degree as the cholesterol concentrations. The most important exception was observed in 
samples from individuals with mutations in the lecithin:cholesteryl acyl transferase (LCAT) 
gene. A reduced LCAT activity appeared to impair the 27OHC esterification in the plasma 
compartment more pronouncedly than the cholesterol esterification. In addition, several 
defects in HDL metabolism led to a re-distribution of 27OHC into apoB-containing 
lipoproteins, which was not observed for cholesterol.  
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An LC-MS method was developed and validated for the analysis of S1P in plasma and 
lipoprotein fractions. The method was subsequently used to investigate the determinants of 
circulating S1P in patients with inborn errors of HDL metabolism. Although only ≤5% of 
HDL particles carry one S1P molecule, both mildly and severely lowered HDL concentrations 
limited the quantity of S1P in plasma. By contrast, high concentrations of HDL-cholesterol 
and apoA-I did not influence S1P levels in plasma. Since S1P exerts several anti-atherogenic 
functions of HDL, these findings are in agreement with the concept of a threshold 
concentration of HDL or apoA-I which is needed for atheroprotection. 
Since there exist biochemical interactions among different lipids involved in 
cholesterol metabolism, profiling of lipids may reveal more key determinants in the 
pathogenesis of atherosclerosis. A sphingo- and phospholipid profiling project has been 
started, in which a method has been developed using a combination of normal phase HPLC 
separation and parent-ion scanning by a triple quadrupole mass spectrometer. Feasibility of 
the method was demonstrated in patients with stable coronary heart disease. 
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ZUSAMMENFASSUNG 
 
Die aktuelle Strategie zur Prävention von kardiovaskulären Erkrankungen beruht auf 
der Risikostratifizierung der Patienten mittels verschiedener Algorithmen. Dies führt jedoch 
bei einer grossen Zahl von Personen zu einer Überschätzung des Risikos. So wird das Risiko 
für ein kardiovaskuläres Risiko zum Beispiel in der Münsteraner PROCAM Studie um 68% 
beziehungsweise 86% bei Patienten mit einem hohen oder intermediären Risiko überschätzt. 
Deshalb braucht es neue Biomarker, die eine bessere und zuverlässigere Einschätzung des 
Risikos ermöglichen. Idealerweise sollte ein Biomarker ein Indikator für normale oder 
pathologische Prozesse sowie das Ansprechen auf therapeutische Massnahmen darstellen. 
Deshalb leiten sich Kandidaten für neue Biomarker für die Erkennung von kardiovaskulären 
Erkrankungen aus der Pathophysiologie der Atherosklerose ab. Mögliche Kandidaten sind 
zum Beispiel 27-Hydroxycholesterin (27OHC), Sphingosin-1-phosphat (S1P), sowie 
allgemein die Sphingo- und Phospholipide. 
Die Forschung in den letzten Jahren hat klar gezeigt, dass das HDL, vor allem durch 
seinen Transport von Cholesterin aus der Peripherie zur Leber (reverser Cholesterintransport), 
eine entscheidende Rolle in der Pathophysiologie der Atherosklerose spielt. HDL hat aber 
auch noch verschiedene pleiotrope Effekte auf das kardiovaskuläre System, welche 
unabhängig vom reversen Cholesterintransport sind. Durch ihre Rollen im HDL Stoffwechsel 
und seinen pleiotropen Funktionen sind 27OHC und S1P in dieser Beziehung von speziellem 
Interesse. 
Publizierte Methoden zur Bestimmung von 27OHC waren zu wenig empfindlich für 
die Bestimmung in Tiermodellen (einzelne Mäuse) oder in der HDL-Fraktion von humanen 
Proben. Aus diesem Grund wurde eine LC-MS – Methode mit Atmosphärendruck 
Photoionisation (APPI) entwickelt und validiert. Die neue Methode ist viel empfindlicher als 
bisher publizierte LC-APCI-MS- oder GC-MS – Methoden und erlaubte uns, Probenvolumina 
von 15 µl mit einer Quantifizerierungsgrenze (LLOQ) von 40 ng/ml oder 4.9 pmol pro 
Injektion zu untersuchen. 
Im Anschluss wurde die Rolle von 27OHC im Verhältnis zum Cholesterinstoffwechsel 
zum ersten Mal in Patienten mit monogenen Erkrankungen im HDL-Stoffwechsel untersucht. 
In den meisten Fällen waren die 27OHC - Konzentrationen in ähnlicher Weise verändert wie 
die Cholesterinkonzentration. Die wichtigste Ausnahme waren Individuen mit Mutationen im 
Gen für die Lecithin-Cholesterin-Acyltransferase (LCAT). Eine Reduktion der LCAT – 
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Aktivität führte zu einer grösseren Reduktion des veresterten 27OHC im Plasma als des 
veresterten Cholesterins. Zusätzlich führten verschiedene Gendefekte im HDL – Stoffwechsel 
zur einer Umverteilung von 27OHC in ApoB enthaltende Lipoproteine. Dieser Effekte wurde 
für das Cholesterin nicht beobachtet. 
Es wurde ebenfalls eine LC-MS – Methode für die Bestimmung von S1P im Plasma 
und in den Lipoproteinfraktionen entwickelt und validiert. Diese Methode wurde 
anschliessend dazu verwendet, die Konzentration von S1P in Patienten mit angeborenen 
Defekten im HDL – Stoffwechsel zu untersuchen. Obwohl nur weniger als 5% der HDL – 
Partikel ein S1P – Molekül beinhalten, führten sowohl leichte als auch massive 
Erniedrigungen der HDL – Konzentration zu einer Beschränkung der S1P – Menge im 
Plasma. Da S1P verschiedene anti-atherogene Funktionen in HDL ausübt, stimmen diese 
Resultate mit dem Konzept, dass es für die Atheroprotektion durch HDL oder ApoA-I eine 
Grenzkonzentration gibt, überein. 
Da es zwischen den verschiedenen Lipiden, die im Cholesterinstoffwechsel eine Rolle 
spielen, unterschiedliche biochemische Interaktionen gibt, können durch das Erstellen eines 
Lipidprofils mehr Schlüssesubstanzen in der Pathogenese der Atherosklerose erkannt werden. 
Ein Projekt zum Profiling von Sphingo- und Phospholipiden wurde initiiert und eine Methode 
entwickelt, die eine Kombination zwischen Normalphasen HPLC und Parent-ion Scan mittels 
eines Triple-Stage-Quadrupol - Gerätes darstellt. Durch das Profiling von Proben von 
Patienten mit stabiler koronarer Herzkrankheit konnte die Anwendbarkeit der Methode 
gezeigt werden. 
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1.  INTRODUCTION 
 
1.1. Biomarkers: Definition and Purposes 
The term biomarker (biological marker) is defined as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention" (1). Hence, the functions 
of biomarkers can shortly be classified into 3 aspects: as indicators of disease trait (or as risk 
factors or risk markers), of disease state (preclinical or clinical), and of disease rate 
(progression) (2). In accordance to these functions, biomarkers can serve as a diagnostic tool 
for the identification of those patients with a disease or abnormal condition, a tool for staging 
or classification of the extent of the disease, an indicator for the disease prognosis, and a tool 
for the prediction and monitoring of clinical responses to intervention. Biomarkers which are 
highly sensitive and specific indicators of disease pathways can serve as surrogate endpoints, 
in which they substitute the clinical endpoints in assessing the benefits and risks of a 
therapeutic intervention in randomized clinical trials. Biomarkers contribute knowledge for 
clinical pharmacology as well as provide bases for designing clinical trials, selection of lead 
compounds for phase III clinical trials, and guidance in dosing (1, 2). 
To be of clinical value, a biomarker must be accurately and reproducibly measured,  
sensitive and specific, acceptable to the patient, and easy to interpret by clinicians for 
diagnostic or prognostic purposes (2). Ideally, a novel biomarker adds clinical value to the 
previously established markers or classical procedures. 
 
 
1.2. The Need for Novel Cardiovascular Biomarkers 
Cardiovascular diseases (CVD), which include coronary heart disease (including 
myocardial infarct / heart attack and angina pectoris / chest pain), stroke, hypertension, and 
heart failure, are the leading causes of disability and mortality in developed countries. An 
alarming increase of CVD in developing countries has also been reported, suggesting that the 
prevention and treatment of CVD is one of the most important public health issues worldwide 
(3). 
 CVD is a life course disease that begins with the evolution of risk factors that in turn 
contribute to the development of subclinical atherosclerosis (2). As a number of CVD events 
occur in asymptomatic patients, prevention includes not only secondary prevention in patients 
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who survive an event, but also primary prevention and hence the early identification and 
treatment of patients at significant risk. Global risk assessment is necessary for accurate risk 
prediction and for the development of appropriate treatment strategies (3). 
 The presence of several moderately expressed risk factors in a given individual – such 
as hypercholesterolemia (high LDL-cholesterol), hypertriglyceridemia, low HDL-cholesterol, 
hypertension, smoking, diabetes, age, male gender, and a positive family history of premature 
atherosclerosis - can produce a significant increase in CVD risk. Therefore at present, the 
most advanced strategy for CVD global risk assessment is to combine the information from 
several risk factors into algorithms or scores. This procedure allows the calculation of an 
individual’s risk within the next 10 years (4). 
 An estimated global risk of >20% per 10 years in an asymptomatic patient is 
considered to be high. The affected patient is given advice to be treated as aggressively as a 
symptomatic patient. This implies lowering of LDL-cholesterol and systolic blood pressure. 
An estimated risk ranging between 10 and 20% in 10 years is considered as moderate, and 
treatment is also targeted to lower LDL-cholesterol and systolic blood pressure. An estimated 
risk <10% is considered as low. In this case, drug treatment recommendations are not offered 
to the majority of individuals (4). 
 In the Munster Heart Study (PROCAM), the finding of an estimated global risk of 
<10% has a negative predictive value of 97%. However, the positive predictive value of the 
high risk estimates (>20%) amounts to maximally 32%, implying a false positive rate as high 
as 68%. The intermediate risk of 10–20% has positive and negative predictive values of 14 
and 86%, respectively (4).  A better risk stratification is clearly needed to optimize the cost-
benefit relationship of preventive measures. Novel biomarkers are one such tool to improve 
risk prediction and clinical assessment.  
 
 
1.3. The Pathophysiology of Atherosclerosis and Lipoprotein Metabolism 
Atherosclerosis is the major underlying cause for CVD events. Despite the old view of 
atherosclerosis resulting from merely a passive deposition of lipids in the arterial wall, many 
studies have recently shown that dynamic inflammation pivotally participates in all stages of 
atherosclerosis, from the initiation to the progression and destabilization of atherosclerotic 
plaques (5). Atherosclerosis begins when the endothelial cells of the blood vessels undergo 
inflammatory activation, leading to an increase in the expression of various leukocyte 
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adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1). VCAM-1 
selectively binds certain leukocyte classes, such as monocyte and T lymphocyte. Leukocytes, 
recruited then by various chemo-attractant cytokines (chemokines), migrate through 
endothelial cell junctions into the arterial intima. Once resident in the intima, monocytes 
acquire the morphological characteristics of macrophages and eventually form the so-called 
foam cells, the cytosolic lipid droplets that appear foamy under the microscope. Foam cells 
are the hallmark of atherosclerotic lesions (5). 
In vitro and animal studies as well as epidemiological studies have shown that 
cholesterol metabolism in macrophages is central to the development of atherosclerosis. 
Cholesterol is transported mainly by plasma lipoproteins in the form of cholesteryl esters. 
Macrophages ingest and digest low-density lipoprotein (LDL)-derived cholesterol by taking it 
up via unregulated scavenger receptors (figure 1). After entering macrophages, cholesteryl 
esters are hydrolyzed by an acid lipase and the free cholesterol is secreted from the cells and 
transported to the liver and steroidogenic organs. However, macrophages take up more 
cholesterol than they can excrete, thus accumulating cholesteryl ester-rich lipid droplets and 
forming the foam cells (6).  
High-density lipoprotein (HDL)-mediated reverse cholesterol transport is the main 
pathway for the efflux of cholesterol from macrophages to the liver. As depicted in figure 1, 
reverse cholesterol transport involves several proteins that directly affect HDL synthesis, 
maturation, conversion and catabolism. Crucial proteins are: apolipoprotein A-I (apoA-I), the 
main protein of HDL which activates lecithin:cholesterol acyl transferase (LCAT), stimulates 
cholesteryl ester efflux and is a ligand for HDL binding sites; ATP-binding cassette 
transporter A1 (ABCA1) which mediates cholesterol and phospholipid efflux from 
macrophages and peripheral cells to lipid-poor apoA-I; LCAT which esterifies cholesterol and 
converts nascent HDL to mature HDL; cholesteryl ester transfer protein (CETP) which 
exchanges cholesteryl ester from HDL with triglycerides from apoB-containing lipoproteins 
and thereby re-generates lipid-poor apoA-I; scavenger receptor type B class 1 (SR-BI) which 
mediates selective uptake of cholesterol into the liver; hepatic lipase (HL) which hydrolyzes 
triglyceride and phospholipids in HDL and is a co-factor of SR-BI in selective uptake; and 
endothelial lipase (EL), an endothelium-derived lipase which preferentially hydrolyzes HDL-
phospholipids, increases susceptibility of cholesteryl ester to SR-BI-mediated selective uptake 
(7, 8). 
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Figure 1. Schematic representation of HDL-mediated cholesterol efflux from macrophages to the liver 
(reverse cholesterol transport), as marked with the blue arrow (). As shown from the cartoon, risk 
factors for CVD (atherosclerosis) include high LDL-cholesterol and low HDL-cholesterol levels. 
 
 
Both genetic and environmental factors determine HDL-cholesterol levels in humans 
and the associated CVD risk. Genetic factors include both frequent polymorphisms with little 
effects on HDL-cholesterol levels and rare mutations with strong effects. The latter include 
mutations in the genes of apoA-I, ABCA1 and LCAT, which cause low HDL-cholesterol 
levels in heterozygotes (frequently below 5th percentile) and virtual absence of HDL in 
homozygotes or compound heterozygotes. By contrast, mutations in the genes of CETP, SR-
BI, EL or HL cause elevations of HDL-cholesterol (9-11). The cardiovascular risk association 
of these mutations is controversially described. Nevertheless, the finding of elevated HDL-
cholesterol levels and reduced cardiovascular risk in Japanese CETP mutation carriers (10-14) 
has stimulated the pharmaceutical industry to develop CETP inhibitors like torcetrapib, 
anacetrapib and dalcetrapib, which are currently under clinical evaluation (15).  
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1.4. Lipids Relevant to the Patophysiology of Atherosclerosis 
1.4.1. 27-Hydroxycholesterol (27OHC) 
 27-Hydroxycholesterol (27OHC) is derived from cholesterol by oxygenation of its 
side-chain at the position C27 (figure 2), formed by the mitochondrial cytochrome P450 sterol 
27-hydroxylase (CYP27). It is the most abundant oxysterol (oxidized cholesterol) in the 
circulation (16) and is part of the cholesterol catabolic pathway to transport excess cholesterol 
from macrophages to the liver. Secretion of 27OHC from macrophages has been proposed as 
an alternative mechanism to the HDL-mediated reverse cholesterol transport (17-19). In the 
liver, 27OHC is an important intermediary product of the so-called alternative bile acid 
synthesis pathway (20). Moreover, 27OHC is one of the activating ligands for the liver-X-
receptors (LXR) which regulate the transcription of several genes involved in cholesterol 
metabolism (21, 22).  
It has been shown that plasma levels of 27OHC correlate with the cholesterol content 
in atherosclerotic lesions and the severity of the disease (23-25). Consistent with this, patients 
with the rare disease of cerebrotendinous xanthomatosis because of mutations in the CYP27 
gene, which cause deficiency of this enzyme, develop premature atherosclerosis despite 
having normal levels of plasma cholesterol (26). Together with CYP27, 27OHC has been 
proposed as a potentially anti-atherogenic molecule (16-18, 27-30). 
 
OH
OH
Figure 2. Structure of 27OHC 
 
 
 
 
 
 
 
 
 
1.4.2. Sphingolipids and Phospholipids 
 Sphingolipids are a family of >300 lipid species which share a sphingoid backbone 
(figure 3). The structural diversity of sphingolipids in mammals includes variations in the 
backbone (sphingosine (d18:1), sphinganine (d18:0) or 4-hydroxysphinganine (t18:0)), fatty-
acid tail (16 to 26 carbon-chain length, 0 to 1 double bonds), as well as in the head group 
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which then determine its sphingolipid class. Head groups include a hydroxyl residue 
(ceramides), phosphates (sphingosine-1-phosphate, ceramide-1-phosphate), phosphocholines 
(sphingomyelins) as well as the combination of glucose and galactose with sialic acid or 
sulphate (glycosphingolipids). The structural diversity of sphingolipids is widely appreciated 
and addressed on a number of “omics” websites, for example SphinGOMAP 
(www.sphingomap.org) (31, 32). 
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 Phospholipids, comprising >700 lipid species, are structurally derived from glycerol 
containing a phosphate group (hence: glycerophospholipids) as well as one (lyso-
phospholipids) or two fatty-acid tails. As with sphingolipids, the variations in the head group 
determine their phospholipid classes (figure 4) as well as their functions in signal 
transduction. Phosphatidic acid is the key precursor of all mammalian phospholipids, as it is 
hydrolyzed and converted into diacyglycerol and cytidine diphosphate (CDP)-diacylglycerols, 
which are then required for the biosynthesis of phosphatidylcholines (PC), 
phosphatidylethanolamines (PE), phosphatidylserines (PS), phosphatidylinositols (PI), 
phosphatidylglycerols (PG), diphosphatidylglycerols (cardiolipins) (33). 
 Sphingolipids and phospholipids are the essential building blocks of all cell 
membranes. The tendency of the hydrophobic moieties to self-associate (entropically driven 
by water), and the tendency of the hydrophilic moieties to interact with aqueous environments 
and with each other, are the physical bases of spontaneous membrane formation. This 
amphipatic property of lipids enables the cells to segregate their internal constituents from the 
external environment as well as the compartmentalization within the cells (34). 
 
 
Figure 3. Sphingolipid structures and head group variation 
polar 
head 
group
R =    H Ceramides (Cer)
Sphingomyelins (SM)
sphingoid backbone
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 In addition to maintaining structural membrane integrity, lipids act as first and second 
messengers in mediating cell-cell recognition and interaction (34). The role of sphingolipids 
and phospholipids in the pathogenesis and progression of atherosclerosis is an area of active 
research (35-41). The phospholipid content in HDL has been shown to have an inverse 
correlation to the incidence of coronary heart diseases, as well as influence SR-BI-mediated 
cholesterol efflux and reverse cholesterol transport (38-41). Experimental data, mostly from 
animal studies, have suggested an association between sphingolipids (particularly 
sphingomyelins and ceramides) with the development and progression of atherosclerosis (37, 
42-47). A few studies in humans have shown that plasma sphingomyelin levels were 
increased in patients with familial high HDL-cholesterol (48) and were associated with 
subclinical atherosclerosis (49) and clinical coronary artery diseases (50, 51). The ratio of 
sphingomyelins to the sum of sphingomyelins and phosphatidylcholines was higher in 
patients with coronary artery diseases. In fact, plasma sphingomyelin and its relative 
concentration to phospholipids (particularly phosphatidylcholines) have been suggested to be 
independent risk factors for atherosclerosis (50, 51). However, a recent large, multi-ethnic, 
Figure 4. Phospholipid structures and head group variation 
R3 =   H
polar 
head 
group
R1, R2 = fatty acyls
Phosphatidic acids (PA)
Phosphatidylcholines (PC)
Phosphatidylethanolamines (PE)
Phosphatidylgylcerols (PG)
Phosphatidylserines (PS)
Phosphatidylinositols (PI)
study showed a contrary finding. High plasma sphingomyelin levels were not associated with 
increased risk, but with a modest reduction of coronary heart disease events after 5 years of 
follow-up (52). Hence, further investigation is needed to reveal the roles and relationships of 
different sphingolipids and phospholipids in CVD events. 
 
 
1.4.3. Sphingosine-1-phosphate (S1P) 
The inverse association between HDL-cholesterol and the risk for cardiovascular 
diseases (53, 54) is usually attributed to the role of HDL in reverse cholesterol transport.  
However, HDL possesses additional pleiotropic functions independent of cholesterol 
metabolism which may contribute to the reduction of cardiovascular risk (55, 56). HDL 
carries the majority of sphingosine-1-phosphate (S1P) in plasma, which is an important 
signalling mediator (56-58). 
 
Sphingomyelins
de novo synthesis of sphingolipids
Ceramides
Sphingosine
Sphingosine-1-phosphate (S1P)
hexadecenal + ethanolamine phosphate
S1P lyase (degradation)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The biosynthesis of S1P  
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S1P is a bioactive lysosphingolipid that is produced primarily by the degradation of 
sphingomyelins into ceramides and sphingosine (figure 5) (59). In vitro and animal studies 
have shown that HDL-associated S1P inhibits the migration of vascular smooth muscle cells 
(VSMCs), promotes nitric-oxide mediated vasodilatation which might be beneficial in 
reducing the blood pressure, promotes endothelial cell growth and survival, inhibits 
endothelial cell expression of VCAM-1 and reduces monocyte and lymphocyte recruitment 
and migration to the arterial intima and hinders foam cell formation (56-60). All reported 
effects of HDL-associated S1P are potentially beneficial for the cardiovascular system (58). 
 
 
1.5. Preview of the Work 
Research over the last decade has revealed that HDL plays a pivotal role in the 
pathophysiology of atherosclerosis, mainly due to its role in removing excess of cholesterol 
from peripheral cells to the liver. However, HDL also displays pleiotropic effects on the 
cardiovascular system, which are independent of its reverse cholesterol transport mechanism. 
27OHC and S1P are the two lipids which are of potential interest, due to their roles in HDL 
metabolism. 
Published studies on 27OHC have indicated its role in an alternative pathway to the 
classical reverse cholesterol transport mechanism, via the conversion of cholesterol to its 
oxidized metabolite by the CYP27 enzyme (29, 61, 62). Hence, measuring circulating levels 
of 27OHC may reflect the activity of this alternative pathway.  
27OHC has been analyzed using gas chromatography – mass spectrometry (GC-MS), 
which gives a good sensitivity albeit laborious sample pre-treatment. A method using liquid 
chromatography – mass spectrometry (LC-MS) with atmospheric pressure chemical 
ionization (APCI) has been developed in our institute (63). However, this method still lacked 
sensitivity for the measurement of 27OHC in animal studies (single mice) and lipoprotein 
fractions. For this reason, an LC-MS method using atmospheric pressure photoionization 
(APPI) was developed to improve the sensitivity. The method was validated as well. 
Subsequently, the role of 27OHC in relation to cholesterol catabolism was evaluated for the 
first time in patients having monogenic disorders of HDL metabolism. 
S1P has been proposed as a potential contributor to the pleiotropic effects of HDL 
independently of reverse cholesterol transport. Although it has been shown to be an important 
signalling molecule, the determinants of S1P levels in plasma have not yet been investigated. 
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An LC-MS method was developed and validated for the analysis of S1P in plasma and 
lipoprotein fractions. The method was subsequently used to analyze S1P in patients with 
monogenic disorders affecting HDL metabolism. 
A few in vitro and animal studies have indicated that some lipids belonging to the 
groups of sphingolipids and phospholipids may play important roles in the pathophysiology of 
atherosclerosis. Thorough investigations of all the different lipid classes and species in these 
lipid groups have not yet been reported. Moreover, the two lipid groups consist of more than 
1000 lipid species with highly heterogeneous molecular structures. The advance of mass 
spectrometry has enabled the analysis of hundreds of lipid species within a single run, 
providing an opportunity to search for potential candidate markers in a high-throughput 
manner. To reach this, an LC-MS-based profiling method was needed to be developed for 
comprehensive analyses of sphingolipids and phospholipids in plasma.  
To summarize, the aim of this work was to establish sensitive and reliable methods for 
the quantification of different lipids and to apply the methods in very well defined patient 
cohorts, namely patients with distinct monogenic disorders of HDL metabolism. Hence, this 
work aimed to set the stage for future evaluation of different lipid candidates in larger-scale 
clinical studies of atherosclerosis. 
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2.  A  BRIEF  OVERVIEW  ON  THE  MASS  SPECTROMETRIC 
ANALYSIS  OF  LIPIDS 
 
 
The term “lipids” is generally referred to a broad group of naturally-occurring 
compounds which have in common a ready solubility in organic solvents, such as chloroform 
and alcohol. However, this description can be misleading since many of the compounds have 
amphiphilic properties and may have higher solubility in water than in organic solvents. An 
interesting definition is given by W.W. Christie (1), who defined lipids as “fatty acids and 
their derivatives, and substances related biosynthetically or functionally to these compounds”. 
This includes a wide range of chemically unrelated groups such as sphingolipids, glycolipids, 
glycerophospholipids (phospholipids), eicosanoids, tocopherols, waxes, triacylglycerols, 
sterols (cholesterol, oxysterols) and fatty acids. For convenience, lipids are referred in this 
text either as groups, classes, or species as classified in table 1.  
 
Table 1. Classification of lipids into groups*, classes and species. The species is lipid molecular species 
with distinct fatty-acid chain structures.  
Lipids 
Group Class Species** 
(examples) 
Fatty acids Free fatty acids 
Eicosanoids 
Palmitic acid, stearic acid 
Arachidonic acid, prostaglandin 
Glycerolipids Triacylglycerols                     
.      
Diacylglycerols 
1,2-Dihexadecanoyl-3-(9Z-octadecenyl)-sn-
glycerol 
1-Palmitoyl-2-oleoyl-gylcerol 
Glycerophospholipids Phosphatidic acids 
Phosphatidylglycerols 
Cardiolipins 
Phosphatidylethanolamines 
Phosphatidylserines 
Phosphatidylinositols 
Phosphatidylcholines 
PA(18:0/0:0), PA(18:0/18:1) 
PG(16:0/0:0), PG(16:1/18:0) 
CL([18:0/16:1],[16:0/18:1]) 
PE(18:0/0:0), PE(18:0/16:0) 
PS(16:0/0:0), PS(16:0/18:1) 
PI(18:1/0:0), PI(18:0/16:0) 
PC(16:0/0:0), PC(18:0/18:1) 
Sphingolipids Long-chain bases 
Ceramides 
Sphingomyelins 
Glycosphingolipids 
Sphingosine, sphingosine-1-phosphate 
Cer(d18:1/16:0) 
SM(d18:1/18:0) 
GlcCer(d18:1/18:0) 
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Table 1. (continued)  
Lipids 
Group Class Species** 
(example) 
Sterols Cholesterol 
Bile acids 
 
Cholic acid 
Prenols Isoprenoids 
Vitamine E  
Diterpenoids 
-tocopherols 
Saccharolipids Lipid A Lipid A-disaccharide-1-phosphate 
*   Modified from ref. (2) 
** For lipid nomenclatures, see ref. (3-4) 
 
Numerous reviews have been published on the mass spectrometric analyses of specific 
lipid groups with emphasis on structural elucidation (5-11), quantitative analysis (12-18) or 
lipid profiling (19-26). This chapter will give a brief overview about current developments in 
the mass spectrometric analysis of lipids in biological samples, with the focus on oxysterols 
(oxidized metabolites of cholesterol), sphingolipids, and phospholipids. 
 
 
2.1. The Nature of the Problem  
 Each lipid group exists in nature as a mixture of closely related molecular lipid 
species. It is hence easier to divide lipid analyses according to two purposes: analyses of 
individual molecular species and analyses of specific lipid groups or classes (in which the 
total lipid species within the class are summed up).  
Lipids generally consist of fatty acids which are linked by ester bonds to alcohols 
(such as to cholesterol) or by amide bonds to long-chain bases (such as in sphingolipids). The 
aliphatic chains are present in various carbon numbers (typically even numbers of 14 to 26 
carbons), various degrees of unsaturation and different attached functional groups (such as 
hydroxyl group and sugars). In addition, variations may also be present at the core lipid 
structures or additional side chains, such as in oxysterols and bile acids. The analysis of lipid 
molecular species is thus a challenge. Nevertheless, complete structural elucidation using 
tandem mass spectrometry has been elegantly demonstrated, for example for oxysterols (27) 
and phospholipids (7, 28). (Semi)-quantification of lipid molecular species is usually sought 
in lipid profiling. One possibility to achieve this is by employing multiple reaction monitoring 
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(MRM) of each species after separation by reverse phase high performance liquid 
chromatography (HPLC), by which the apolar fatty acid chains are retained on the HPLC 
column (16-17). Upon different approaches, lipid groups such as sphingolipids and 
phospholipids are sub-grouped into classes based on their polar head groups. Profiling of one 
or a few lipid classes is then conducted by direct-infusion into the MS (29-32) or with prior 
separation of the different classes by normal phase HPLC (33-35). Quantification, however, is 
complicated by the fact that different numbers of carbons and double bonds in the fatty acid 
chains affect the ionization efficiency of each molecular species (36). 
The analysis of total lipids within a specific lipid group often employs acid and/or 
alkaline hydrolysis to break the fatty acyl amide and ester. This has been applied, for 
example, to the quantification of oxysterols (37-39) and long-chain sphingoid bases (16).  
 
 
2.2. Hyphenated Techniques for Targeted Lipid Analysis 
 For the analysis of simple lipids, for example fatty acids, gas chromatography – mass 
spectrometry (GC-MS) is currently still the “standard”, well-established technique, although 
the sample pre-treatment is quite laborious due to the need of prior derivatization of the non-
volatile lipids (40-44). In recent years, liquid chromatography – mass spectrometry (LC-MS) 
has become a more common technique for lipid analysis (20-21). Both electrospray ionization 
(ESI) and atmospheric pressure chemical ionization (APCI) can be employed for the analysis 
of sphingolipids, phospholipids and sterol derivates (such as oxysterols) (27, 45-47). 
However, for sensitivity reasons, quantification of most sphingolipids and phospholipids 
utilizes ESI (11, 16-17), while oxysterols (without derivatization) are better ionized with 
APCI (38, 48). Recently, a new interface utilizing atmospheric pressure ionization (APPI) 
emerged (49-50) and has been shown to improve the sensitivity for the detection of oxysterols 
and other sterol derivates (37, 51-52). 
 
 
2.2.1. Atmospheric Pressure Photoionization (APPI)  
 Photoionization (PI) itself is not a revolutionary technique and has been used in GC 
with photoionization detector (PID) and in ion-mobility spectrometry (IMS) (49). However, 
the hyphenation to LC-MS was first introduced by Robb et al only in 2000 (53).  
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 APPI is based on the interaction between the photon beam produced by a discharge 
lamp (usually a Kr-filled UV lamp which has lower photon energy (10 eV) than the major 
components of air) and the vapor produced from the nebulization of solvent and analyte 
mixture. PI occurs in several steps. First, the analyte or solvent molecule (M) is excited due to 
the absorption of a photon (E = h) (49-50): 
 
M + h → M* 
 
When the ionization energy (IE) of the molecule is lower than the photon energy, an energetic 
electron is released (Ee− (max) = h − IEM), leading to a molecular ion with an unpaired 
electron (49-50): 
M* → M•+ + e− 
 
When the IE of the molecule is higher than the photon energy, de-excitation may occur (49-
50): 
 photodissociation :   M*→ A + B 
 photon emission :   M*→ M + h 
 collisional quenching :    M* + C → M + C*  
 
Ideally, the energy of the ionizing photon needs to be higher than the IEs of the target analytes 
and lower than the IEs of the constituent air and solvents. When this is not the case, however, 
adding a relatively high amount (as compared to the analytes) of additional substances called 
dopant may help to increase the probability of analyte ion formation. Depending on the proton 
affinity (PA) and/or electron affinity (EA) of its photoions, the dopant (D) functions as an 
intermediate between the analyte and photon reaction via proton transfer mechanism (49-50): 
 
 proton transfer : D•+ + M → [D − H]• + [M + H]+ if PAM>PA[D−H]• 
 
The sensitivity that can be achieved using APPI hence directly depends on the reactant 
ion composition, which in turn depends on the presence of the analytes, the impurities, the 
solvents, the dopant, and the nebulizing gas as well as the components of the surrounding air 
(49-50, 54). 
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2.3. Lipid Profiling  
Due to the advances of mass spectrometry and the need to understand the complexity 
of lipid biochemistry, lipid analysis has been focusing on lipidomics which can been defined 
as “the full characterization of lipid molecular species and of their biological roles with 
respect to expression of proteins involved in lipid metabolism and function, including gene 
regulation” (55). Different mass spectrometric techniques have been employed for this 
comprehensive lipid analysis, both for the structural characterization and (semi)-
quantification of the lipid species. One practical outcome of this practice is the discovery of 
novel lipid species by (tandem) mass spectrometry (56-59).  
Among the numerous mass spectrometry-based methods that have been developed for 
lipid profiling, the most commonly used are: “shotgun lipidomics” (intra-source separation 
and single parent-ion or neutral-loss scans with a direct infusion), multiple parent-ion or 
neutral-loss scans (with and without data-dependent acquisition control), and multiple-
reaction monitoring (MRM) after reverse phase chromatographic separation (19-21, 23).  
 
 
2.3.1. Shotgun Lipidomics 
In principal, shotgun lipidomics is an intra-source separation and selective ionization 
of lipids and their lithium adducts, as depicted in figure 1. Total lipid extracts are infused 
directly into the ESI source and lipid species are subsequently identified in a triple quadrupole 
mass analyzer using lipid class-specific parent-ion scans and neutral-loss scans. By varying 
the solvent composition and spraying conditions, it is possible to specifically enhance the 
ionization of certain lipid classes and, hence, to improve the dynamic range of lipid detection 
(60-61). This approach has been applied to profile lipid species of different phospholipid 
classes (29, 31, 62-71).  
The major drawback of this technique is the ion suppression of the low abundance 
lipids and the contamination of the instrument with lithium ions (61). 
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Figure 1. Intra-source separation and selective ionization of lipids (61) 
 
 
2.3.2. Multiple Parent-ion Scans (MPIS)  
Similar parent-ion scan experiments like shotgun lipidomics can also be performed on 
a Q-TOF instrument. In contrast to the triple quadrupole, in which each parent-ion spectrum 
can only be acquired sequentially in time, QTOF has the advantage that multiple parent-ion 
scans (MPIS) can be acquired at the same time and that the fragment ions are detected at a 
high accuracy. This MPIS is achieved by stepping the quadrupole across the desired parent 
mass (m/z) range and recording all the obtained MS/MS spectra. Data are generated to allow 
deconvolution or the ‘‘construction’’ of multiple parent-ion spectra (72).  
An alternative to this approach has been developed utilizing data-dependent 
acquisition control. In this approach, a survey scan is first performed to detect parent-ions of 
interest in the sample. MS/MS is then performed only on targeted parent-ions. This method 
can be conducted on a QTOF or on hybrid FT-ICR or Orbitrap instruments; the latter gives 
the advantage of high accuracy and sensitivity for the detection of the fragment ions (73-74).  
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2.4. Quantitative Analysis and Validation 
 Validation of analytical methods is important in order to ensure that the analysis of 
samples gives reliable and reproducible results. The essential parameters required according 
to the official guides such as the FDA Guidance for Bioanalytical Method Validation (75) are 
selectivity, sensitivity, accuracy, precision, reproducibility, and stability. Other parameters are 
usually also determined during validation, for example: extraction efficiency, linear dynamic 
range, matrix suppression and dilution integrity for analyzing analyte with concentration 
above the upper limit of quantification (76). 
As opposed to targeted analysis, results obtained from profiling-based methods are 
much more difficult to assess due to the much larger numbers of measured analytes as 
compared to the numbers of replicates, the inadequacy of the existing methods to provide 
selectivity and accurate quantification, and the still lack of standard protocols for validation 
(77-79). Particularly in lipid profiling, different techniques exist; each has its own limitation, 
which can compromise the reliability of quantitative analysis. For example, it is frequently 
impossible to obtain deuterated standards for each lipid species. Non endogenous lipids with 
odd numbers of carbon in the fatty acid chains hence are used as internal standards. However, 
different numbers of carbons and double bonds in the fatty acid chains affect the ionization 
efficiency of each molecular species (36), leading to inaccurate quantification. Although 
comparative profiling can be done to reveal lipids that show differences between sample 
clusters (22), these results can be difficult to reproduce in other studies (77). Moreover, due to 
the long carbon chains of the fatty acyls, deisotoping is needed to correct the overlapping 
isotope peaks with adjacent masses. Han and Gross et al addressed these two problems by 
employing correction factors for C13 isotopes and for the carbon number differences between 
internal standards and target analytes. However, the correction factor for the carbon number 
differences depends on the specific lipid class and must be determined experimentally. 
Furthermore, selectivity is still a problem as their quantification is complicated by the 
presence of isobaric lipid species (61, 80).  
In the context of novel biomarker discovery, a candidate novel marker needs to undergo 
verification and clinical evaluation to determine its sensitivity and specificity in indicating 
abnormal conditions. Before this clinical verification, the analytical performance of the novel 
candidate needs to be assessed so that its accuracy and precision is demonstrated (validated) 
(81-82). Hence, similar to targeted analysis, several parameters need to be assessed in 
profiling-based method. One example to achieve this is by using various non-endogenous 
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lipid class-specific internal standards spiked to plasma matrix to assess the linearity, limit of 
detection, repeatability and recoveries of the method (83). However, this approach only 
provides an indication for the reliability of the endogenous analytes measurement, due to the 
differences in the abundance and ionization efficiency of different lipid species. As yet, the 
best option offered to accurately quantify lipids is by employing multiple reaction monitoring 
(MRM) and stable isotope dilution on targeted lipid species chosen from profiling approach, 
as this is amenable to standard quantitation and analytical quality controls (77, 79, 82, 84-85).  
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Abstract 
27-Hydroxycholesterol (27OHC) is of potential diagnostic interest due to its role in 
maintaining whole-body cholesterol homeostasis. DA-APPI (Dopant Assisted - Atmospheric 
Pressure Photoionization) has improved the sensitivity of 27OHC analysis, in comparison to 
the published LC-APCI-MS method, allowing quantification from a very low amount of 
sample ( 50 µL plasma). The method was validated for quantification from 50 L and 15 L 
plasma, with the limit of quantification (LOQ) of 10 and 40 ng/ml plasma, respectively. A 
further advantage is that no prior derivatization was needed, unlike the LC-ESI-MS or the 
standard GC-MS method. The method validation also resulted in good linearity and recovery 
of 91% to 106%. The within-day and between-day coefficient of variation were less than 15% 
while giving the accuracy of 90.9% to 113.4%. This report summarizes the effects of some 
critical parameters on the ionization of 27OHC using APPI, as well as the validation of the 
method. The sensitivity achieved with DA-APPI broadens the usefulness of the LC-MS 
method in clinical applications.  
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3.1. Introduction 
27-Hydroxycholesterol (27OHC) is an oxygenated metabolite of cholesterol formed 
by the sterol 27-hydroxylase (CYP27), an enzyme which is widely distributed among tissues 
and organs, particularly in vascular endothelium and macrophages (1-3). The oxidation at the 
C27 of the cholesterol side-chain is part of the cholesterol catabolic pathway to transport 
excess cholesterol from peripheral cells to the liver, as the metabolite is then able to pass 
lipophilic membranes quicker, and is the first intermediate in the synthesis of the more 
hydrophilic bile acids (4). 27OHC is one of the oxysterols (oxidized cholesterols) that 
function as activating ligands for the liver-X-receptors (LXR), regulating the transcription of 
genes involved in cholesterol catabolism, transport and elimination (5). The importance of 
27OHC is mostly attributed to its role in maintaining cholesterol homeostasis, since it 
provides an alternative route to the main HDL-dependent reverse cholesterol transport and 
represents a potential anti-atherogenic effect (1-4, 6-9). It has been shown that patients with 
cerebrotendinous xanthomatosis, a deficiency in the CYP27 caused by mutations in the 
coding gene, suffer from premature atherosclerosis despite having normal levels of plasma 
cholesterol (10). The plasma level of 27OHC also correlates with the cholesterol content in 
atherosclerotic lesion and the severity of the disease (11-14). Recently, there is a growing 
interest in the role of 27OHC in diseases with disturbed cholesterol homeostasis 
(atherosclerosis) such as neurodegenerative diseases (cognitive decline in elderly, 
Alzheimer’s disease) and breast cancer (15-18).  
 Considering the potential diagnostic interest of 27OHC particularly for improving 
cardiovascular disease risk-assessment, the limited sample volume that might be obtained 
from animal models and plasma lipoprotein subfractions, the low endogenous levels of 
27OHC and the presence of interferences such as cholesterol which is present at 103-106 
higher endogenous level, an accurate, sensitive and selective analytical method is important.   
 For more than a decade, GC-MS has been a well-established method to quantify 
cholesterol and its oxidation products. The method requires prior derivatization of alcohol 
groups to trimethylsilyl (TMS) ethers (19). The very low injection volume of the GC-MS 
system (~2 L) gives advantage in allowing preconcentration of the target analyte, 
contributing to the high sensitivity achieved by this method. 
 LC-MS has also been introduced for the analysis of cholesterol oxidation products, 
either utilizing an ESI or APCI interface depending on the aim of the analysis. Using ESI for 
the oxysterols needs both derivatization and downscaling to nanoscale to achieve a high 
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sensitivity. One of the successful applications is the conversion of the hydroxyl group of the 
steroid ring into an oxo group with cholesterol oxidase, hence gives broader options for 
derivatization reagents. Using this approach and subsequent derivatization with Girard P 
reagent, structurally rich tandem MS spectra with a sub-pg sensitivity has been achieved by 
Griffiths et al (20).  
 The oxysterols can be well ionized without any prior derivatization using APCI, which 
is advantageous over the ESI and the GC-MS methods.  Hence, the sample preparation can be 
faster and less laborious. The [M+H-H2O]+ ion produced by the APCI is not structurally 
informative since stable and structure-specific tandem MS spectra cannot be obtained. Thus, 
the confirmation for which C position the cholesterol is oxygenated is obtained from the LC 
retention time in comparison with reference standards. This method has been previously 
developed in our lab and has been used to establish the normal reference values of 24S- and 
27OHC in human plasma (21). Starting with 500 L plasma and 5 times preconcentration 
prior to the LC-MS analysis, the method is able to achieve a detection limit of 25 ng/ml 
plasma (22). However, due to the need to analyze smaller amounts of plasma, we investigated 
the possibility to enhance the sensitivity of the method using APPI. 
 Photoionization itself is not a revolutionary technique and has been used in gas 
chromatography (PID detector) and in ion-mobility spectrometry (IMS) (23). However, the 
hyphenation to LC-MS was first introduced by Bruins et al only in 2000 (24). Since then, 
APPI has been believed to be able to compensate the drawbacks from the older ESI and APCI 
sources. In a few published applications, APPI has been reported to extend linear dynamic 
range (25), reduce or omit offline sample cleanups (26-27) and generally lower detection limit. 
Especially in the area of lipid analysis, APPI has been discussed as a promising technique 
(28-30). 
 The ionization process in APPI directly depends on the reactant ion composition, 
which in turn depends on the presence of the dopant, the solvent, the nebulizing gas, the 
auxiliary gas, and the impurities as well as the components of the surrounding air (31). In this 
report, some critical APPI parameters for improving the sensitivity of 27OHC have been 
investigated.  
 Since 27OHC in plasma is about 85-90% esterified with fatty acids, a hydrolysis step 
prior to the sample cleanup was conducted whenever the total amount of endogenous 27OHC 
was analyzed (19, 21). Subsequent sample preparation using a solid-phase extraction method 
was as described by Burkard et al (22). Validation results of the method are presented.   
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 DA-APPI (dopant-assisted APPI) improved the sensitivity for the quantification of 
27OHC, in comparison to the previous LC-APCI-MS method (22), allowing the 
quantification from as little as 50 L plasma with the limit of quantification (LOQ) of 10 
ng/ml plasma. The method was also validated for analyzing 15 L plasma, with the LOQ of 
40 ng/ml plasma. The sensitivity achieved broadens the usefulness of the LC-MS method in 
clinical applications.  
 
 
3.2. Experimental 
3.2.1. Chemicals and Reagents 
27OHC was purchased from Medical Isotopes (Pelham, NH, USA). The deuterated 
internal standard, 27OHC-d6 ([1,2,3,4,4,6-2H6] C5-3,27-diol), was obtained from Sugaris 
(Muenster, Germany). All chemicals were purchased from Fluka (Buchs, Switzerland). All 
solvents were of HPLC grade and obtained from SDS (Cedex, France). Blank plasma was 
obtained from healthy volunteers. 
 
 
3.2.2. Sample Collection  
Blood was collected in evacuated blood collection tubes containing EDTA (3 ml 
Vacutainer, 0.184 M K3EDTA; Becton Dickinson, Basel, Switzerland). The sample was 
centrifuged at 2000x g for 10 min and stored at -20°C.  Upon analysis, the plasma samples 
were thawed and 10 L butylated hydroxytoluene (5 mg/ml solution in methanol), which 
served as an antioxidant, was added per milliliter plasma prior to hydrolysis and / or solid-
phase extraction.  
 
 
3.2.3. Sample Preparation 
3.2.3.1. Hydrolysis of 27OHC Esters 
The hydrolysis of the 27OHC esters was conducted whenever the total endogenous 
27OHC was analyzed. To 15 L undiluted plasma, 150 L 1 M ethanolic sodium hydroxide 
was added, followed by 50 L internal standard solution (100 ng/ml 27OHC-d6 in methanol). 
The alkaline hydrolysis was performed for 2 h at 50°C in a water bath. The hydrolyzed 
plasma was subsequently neutralized to pH 7 with 50% phosphoric acid and 200 L 
 48
phosphate buffer pH 7. The mixture was then centrifuged for 5 min at 1000x g and the 
supernatant was taken for the subsequent solid-phase extraction. 
 
 
3.2.3.2. Solid-phase Extraction 
The solid-phase extraction was performed using C18 cartridges (200 mg, Bond Elut; 
Varian, Zug, Switzerland). The column was preconditioned with 1 ml n-heptane/2-propanol 
(50:50 v/v), 1 ml methanol and 2 ml water. The sample was applied to the cartridge using 
only gravity (no vacuum was applied to the chamber of the solid-phase extraction manifold). 
The cartridge was then washed with 4 ml methanol/water (75/25 v/v) and briefly dried under 
vacuum. Elution of the analyte was done using 2 ml n-heptane/2-propanol (50:50 v/v) using 
only gravity. The eluted components were dried by evaporation at 30°C (Rotavapor; Büchi, 
Flawil, Switzerland). The residue was reconstituted in 50 L methanol/HCOOH 0.1% (85:15) 
and 40 L was injected to the LC-MS system. 
 
 
3.2.3.3. Sample Preparation for Validation Purposes 
For the determination of the precision, accuracy and the LOQ, non-hydrolyzed diluted 
plasma was used because spiking of hydrolyzed undiluted plasma with 27OHC was not 
possible (see “Results and Discussion”). Stored plasma was first thawed and butylated 
hydroxytoluene was added as described in the “Sample Collection” previously. Then, four 
parts of water were added to one part of plasma (yielding a dilution of 1:5). Different 
concentration of 27OHC standard solution was spiked to this diluted plasma as described in 
the section of “Method Validation” below. Aliquots of either 15 L or 50 L diluted plasma 
were then taken. Internal standard solution was subsequently added. Ethanol (100 L) and 
phosphate buffer pH 7 (~ 200 L) were added to increase the final volume and the subsequent 
solid phase extraction was then performed. 
 
 
3.2.4. LC-MS system 
The LC system consisted of a Rheos 2000 pump (Flux Instruments, Basel, 
Switzerland) and an HTC PAL autosampler (CTC Analytics, Zwingen, Switzerland). The MS 
system was the LCQ Deca XP Max (Thermo Fisher Scientific, Waltham, MA, USA) which 
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had a three-dimensional ion trap mass analyzer. The vaporizer temperature and the capillary 
temperature were set at 400°C and 190°C, respectively. The protonated-and-dehydrated ion 
[M+H-H2O]+, m/z 385.2, was monitored in single ion monitoring (SIM) mode with 3 amu 
scan-width. The duty cycle was ~350 milliseconds. Data acquisition was performed using 
Xcalibur software (Xcalibur 2.0, Service Release 2). During the APPI ionization, it was 
observed that high sheath gas and auxiliary gas pressure was needed to achieve good 
sensitivity, despite the composition of the mobile phase which had 95% methanol. 
 The separation was performed using a reversed-phase LC column (Nucleosil HD, 250 
x 4.6 mm, 3 m). The eluent A was methanol and the eluent B was formic acid 0.1%. The 
elution of 27OHC was performed isocratically with 95% eluent A and 5% eluent B. However, 
the washing of other contaminants such as endogenous cholesterol required gradient elution to 
methanol 100%. Hence for the first 5 min, the mobile phase was methanol/HCOOH 0.1% 
(95:5) pumped at 800 L/min. Within the subsequent 0.5 min, the mobile phase flow rate was 
decreased to 400 L/min to ensure the separation of 27OHC from the co-eluting contaminants. 
After 12 min, the mobile phase composition was changed to 100% methanol for 10 min at 
800 L/min to wash some lipophilic contaminants from the column. The small particle size of 
the column (3 m) did not permit a higher flow rate since the back pressure became very high. 
The re-equilibration of the column as well as further removal of contaminants followed, using 
methanol/HCOOH 0.1% (95:5) at 800 L/min. 
 
 
3.2.5. Method Development 
3.2.5.1. Ionization of 27OHC using APPI 
The optimal conditions needed for the ionization of 27OHC with APPI were 
investigated by direct infusion of the analyte. A solution of 27OHC (1 g/ml in methanol) 
was introduced to the LC eluent with a syringe pump at 10 L/min. The eluent was 
methanol/HCOOH 0.1% (95:5) or otherwise mentioned in the “Results and Discussion”. The 
eluent was introduced using an LC pump at 400 L/min. When conducting the DA-APPI, 
toluene (dopant) was introduced to the mixture of eluent and sample before entering the 
ionization chamber, using a tee and a second LC pump (Shimadzu LC-9A pump, Shimadzu, 
Kyoto, Japan). The flow rate of the dopant was 100 L/min or otherwise mentioned in the 
“Results and Discussion”. 
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 The dual-source experiment was carried out by turning on and off the corona needle 
voltage or the UV lamp. The mass spectrometer used had both APCI and APPI sources built 
in one ionization chamber to be used together without the need to remove or replace any 
hardware. The MS parameters were optimized (tuned) for APCI and the corona needle, when 
it was used, was set as giving a 4 A current. 
 
 
3.2.5.2. Ion Suppression Test  
The test for ion suppression was carried out according to the postcolumn infusion 
system used by King et al (32), with an additional tee for the introduction of the APPI dopant 
(toluene) to the system. A solution of 27OHC (1 µg/ml in methanol) was post-column infused 
through a zero dead volume tee to the LC eluent at 10 L/min using a syringe pump equipped 
in the LCQ Deca XP Max system. Prior to entering the ionization chamber, a second tee 
was installed for the post-column infusion of toluene (100 L/min) to the mixture of sample 
and LC eluent using a Shimadzu LC-9A pump (Shimadzu, Kyoto, Japan) 15 µL blank plasma 
were hydrolyzed and extracted as described previously and injected into the LC-MS system 
by the autosampler. All other LC-MS conditions were as described previously. 
 
 
3.2.5.3. Assessing the Linearity in Plasma Matrix 
Calibration curves were constructed to assess the linearity between the response and 
the spiked concentration of the analyte. From the 1 µg/ml and 10 µg/ml standard solution of 
27OHC in methanol, different aliquots were taken to make standards in plasma. To the 
aliquots of 10, 20 and 50 µL of 1 µg/ml methanol standard solution, plasma was added until 
the final volume was 1 ml, hence yielding plasma standards of 10, 20 and 50 ng/ml. To the 
aliquots of 10 and 25 µL of 10 µg/ml methanol standard solution, plasma was added until the 
final volume was 1 ml, hence yielding plasma standards of 100 and 250 ng/ml. 100 µL of 
each plasma standard, as well as a non-spiked plasma to serve as a blank and for background 
subtraction, were pipetted in clean tubes. The deuterated internal standard was then added, the 
mixture was hydrolyzed and the solid-phase extraction was performed as described previously. 
Reconstitution following the evaporation step was either in 100 µL mobile phase or in 500 µL 
mobile phase (to obtain 5 times dilution). The whole procedure was conducted in triplicates 
for each different concentration.  
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 The dilution curve was constructed between the response and the estimated 
endogenous 27OHC concentration. One part of plasma was added to 1 part of water, yielding 
a dilution of 1:2. Subsequently, this twice-diluted-plasma was diluted again 1:2. This was 
done consecutively, hence the final dilution made were 1:2, 1:4, 1:8, 1:16 and 1:32. From 
each dilution, aliquots of 50 µL and 100 µL were taken. These diluted plasma samples were 
then hydrolyzed, the solid-phase extraction was performed and the sample was reconstituted 
either in 50 µL (for the 50 µL aliquot) or 100 µL (for the 100 µL aliquot) mobile phase. The 
aliquoting and subsequent sample preparation were conducted in triplicates. The dilution 
curve was then constructed between the peak area and the calculated endogenous 27OHC 
concentration in each dilution.  
 The endogenous 27OHC concentration of the dilution curve was calculated from the 
ratio of the response between the spiked plasma (containing unknown plus known 
concentration) and the blank (containing unknown concentration). Two aliquots were taken 
from the undiluted plasma, one of them was spiked with 50 ng/ml 27OHC standard solution. 
These samples underwent the same sample preparation procedure and were analyzed at the 
same time as the diluted plasma above. 
 
 
3.2.6. Method Validation 
3.2.6.1. Linearity 
The calibrator standards were prepared in methanol. Defined amounts of 27OHC and 
the deuterated internal standard (100 ng/ml) were dissolved in methanol, evaporated and 
reconstituted in 50 L methanol/HCOOH 0.1% (85/15) prior to the LC-MS analysis. The 
concentration of 27OHC in the reconstituted calibrator standards ranged between 10 to 250 
ng/ml. The calibration curve was plotted as the peak area ratio of 27OHC to the internal 
standard vs. concentration.  
 
 
3.2.6.2. Recovery  
Defined amounts of 27OHC were added to 15 µL plasma (samples) and to clean vials 
(standards). Six replicates were performed for each spiked concentration, both for the samples 
and the standards. The samples were hydrolyzed and extracted as described in the “Sample 
Preparation”, whereas the standards were only evaporated, reconstituted and injected to the 
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eviously. 
LC-MS. The recovery was determined by comparing the average peak areas of the samples to 
the average peak areas of the standards. 
 
 
3.2.6.3. Precision and Accuracy 
As described in “Sample Preparation for Validation”, different concentrations of 
27OHC standard solution in methanol were spiked to the non-hydrolyzed diluted plasma. 
Aliquots of 15 µL or 50 µL were then taken.   
 To the 50 µL aliquots of diluted plasma, 27OHC standard solution had been added to 
give the final concentration of 10 and 40 ng/ml, respectively. To the 15 µL aliquots of diluted 
plasma, higher concentrations of 27OHC standard solution had been added to give the final 
concentrations of 40, 125 and 200 ng/ml. Subsequently, 50 µL internal standard solution (100 
ng/ml 27OHC-d6 in methanol), 100 µL ethanol and 200 µL phosphate buffer pH 7 were 
added. The solid-phase extraction and the subsequent LC-MS analysis were performed as 
described pr
 Six replicates of each concentration were analyzed within one day to determine the 
within-day precision and accuracy. Six replicates of each concentration were analyzed on six 
different days to determine the between-days precision and accuracy.  
 The precision was expressed as the coefficient of variation of the assayed 
concentrations. The accuracy was assessed as the bias of the assayed concentration to the 
weight-in concentration. 
 In addition, the between-days precision was also confirmed in a hydrolyzed, undiluted 
plasma sample. After thawing and the addition of butylated hydroxytoluene, 15 µL plasma 
directly underwent the hydrolysis and solid phase extraction procedure as described in the 
“Sample Preparation” previously. This was done to confirm the precision of the measurement 
in real plasma samples. 
 
 
3.2.6.4. Limit of Quantification (LOQ) 
The LOQ was determined by assessing the results from the within-day precision. The 
LOQ was determined as the lowest spiked concentration with a calculated imprecision of less 
than 15%.  
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3.3. Results and Discussion 
3.3.1. Method Development 
3.3.1.1. Ionization of 27OHC using APPI 
For trace bioanalysis, fine-tuning of all parameters to optimize the ionization 
efficiency is needed to achieve higher signal-to-noise ratios. Thus, the effects of different 
dopants, dopant flow rates, different solvents and the use of the dual-source on the ionization 
of 27OHC were investigated. 
 Figure 1 shows the mass spectra observed for 27OHC. Both APPI and DA-APPI 
(dopant-assisted APPI) of 27OHC gave the protonated-and-dehydrated molecular ion, [M+H-
H2O]+, as the most prominent observed ion, indicating that a chain of ion-molecule reaction 
occurred following photoionization.  
A direct photoionization of an analyte molecule is believed to be a statistically 
unlikely event, partly because the large excess of solvent molecules may undergo 
photoexcitation and deplete the limited photon flux (23-24). For a compound to be 
photoionized, it needs to have a gas-phase ionization potential (IP) lower than the photon 
energy emitted by the lamp (10eV for the Kr-filled lamp used in this experiment). Most LC 
solvents have higher IP, so that the number of primary ions produced by a discharge lamp is 
very low. However, the percentage of ionizable molecules in vaporized LC eluent can be 
raised significantly by the addition of a large quantity of dopant. The dopant photoions 
subsequently ionize the target analyte by proton transfer or charge exchange. Theoretically, 
there are many substances having lower IP than the photon energy of a discharge lamp. 
However, only a few have been tested with LC-APPI-MS and the majority of published 
applications make use of acetone (IP 9.70 eV) and, more favorably, toluene (IP 8.83 eV). 
Figure 2 shows that acetone and toluene enhanced the ionization efficiency of 27OHC 2 and 5 
fold, respectively. Bruins et al suggested that, in the case when proton transfer is the main 
occurring ion-molecule reactions, toluene acts as dopant towards a wider range of compounds 
(those with both low and high proton affinity (PA) in comparison to acetone (24). The high 
ionization efficiency achieved during APCI and solvent-mediated DA-APPI suggested that 
27OHC has high PA. Empirical evidence for the mechanisms leading the ionization of 
27OHC is outside the scope of this paper though. 
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Figure 1. Full-scan mass spectrum of 27OHC showing prominent [M+H-H2O]+ ion (m/z = 385.2) 
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Figure 3 shows the increasing response of 27OHC with increasing toluene flow up to a 
certain rate (the eluent flow was kept constant). Above 0.05 ml/min toluene, the observed 
27OHC signal reached a plateau. This result was qualitatively in agreement with the 
mechanistic study conducted by Blades et al (33). One of the possible explanations proposed 
by Blades et al is the loss of ions due to the recombination of oppositely-charged species, 
whose rate is in quadratic dependence on the charged-particle density. Within the field-free 
region of the APPI source, the separation of oppositely-charged species does not immediately 
follow the ionization process; hence, neutralization via recombination may occur. Raising the 
lamp current increases the primary ion generation, but this cannot overcome the apparent limit 
in the signal trend. In a separate experiment, Blades et al also noted that a significant gain in 
the primary ion production can actually still be obtained by raising the dopant flow rate even 
above 0.1 ml/min (33). Thus, the asymptotic intensity of the analyte signal with the increasing 
dopant flow was not due to the limitation in the primary ion production.  
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Figure 3. Effect of toluene flow rate on the signal intensity of 27OHC 
 
 The composition of the LC eluent has an impact not only on the chromatographic 
separation, but also on the ionization efficiency of 27OHC. It has been described previously 
that the LC eluent as well as impurities present in the solvent might influence the ionization of 
a target analyte (23-24, 31). 
 The published LC-APCI-MS method for 27OHC utilized a reversed-phase column for 
LC separation(22). However, the sample preparation of 27OHC in published GC-MS methods 
utilized the hydrophilic silica material for solid-phase extraction(4), suggesting that the 
separation of 27OHC could be conducted also in normal-phase HPLC. Figure 4 shows the 
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effect of several common reversed-phase and normal-phase HPLC solvents to the sensitivity 
of the DA-APPI of 27OHC. Methanol was found to assist the ionization of 27OHC as the 
signal intensity observed was profoundly enhanced. This phenomenon is generally attributed 
to the interaction between methanol and a toluene radical cation forming a cluster. Kauppila et 
al described the formation of trimer and possibly higher order methanol clusters. Individual 
monomers of the solvent have a lower PA than the benzyl radical, so the proton transfer 
between the toluene radical cation and the solvent molecules cannot take place. However, the 
solvent cluster has a higher PA than its individual monomer and its proton transfer with 
toluene photoion is then thermodynamically possible. The protonated solvent species can then 
subsequently ionize the target analyte molecules (23, 31). 
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Figure 4. Effect of different solvents on the signal intensity of 27OHC 
 
 As shown in Figure 4, using acetonitrile or the combination of methanol and 
acetonitrile severely decreased the ionization efficiency of 27OHC. Acetonitrile or the 
combination of methanol and acetonitrile were actually favorable for the reversed-phase 
HPLC eluent, as it gave better peak shapes, more selective separation and lower back pressure. 
However, the LC-APPI-MS method developed in this paper used methanol/HCOOH 0.1% 
(95/5) due to the sensitivity achieved. Using HCOOH 0.1% in the eluent did not compromise 
the sensitivity of the method (data not shown).  
 27OHC is a relatively non-polar compound and lacks acidic or basic groups to be well 
ionized by ESI. On the other hand, APCI can give good sensitivity, although it is still not high 
enough for our purposes. Since both APCI and DA-APPI give the same type of observed 
27OHC ion ([M+H-H2O]+), we have investigated the possibility to improve the sensitivity by 
using both ionization sources together. A few successful experiments using a dual-source 
have been reported by Syage et al (34). Excess of electrons from the corona needle might 
interfere with the ion-molecule reactions during APPI though, resulting in the competition or 
recombination of ions. From Figure 5, it can be seen that the DA-APPI process was depleted 
when combined with APCI for the analysis of 27OHC. The DA-APPI alone increased the 
signal intensity of 27OHC by a factor of 2.5, as compared to the dual-source approach. 
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Figure 5. Effect of different ionization modes on the signal intensity of 27OHC 
 
 
 
3.3.1.2. Matrix Substitution for Calibrator Standard 
One of the difficulties in developing methods for the purpose of biomarker studies is 
the unavailability of analyte-free matrix. The plasma concentration of total 27OHC in healthy 
volunteers is in the range of 95-300 ng/ml(22). A non-linear response and large random 
variation have been observed during the addition of 27OHC standard solution to 100 µL of 
plasma (Figure 6a) or even diluted plasma (Figure 6b), which seemed like approaching 
plateau as the spiked concentration was increased. When the same plasma was simply diluted, 
a linear relationship could be determined between the dilution factor and the signal (Figure 7). 
 0.00 
2.00 
4.00 
6.00 
8.00 
10.00 
12.00 
0 20 40 60 80 100 120 C
or
re
ct
ed
 p
ea
k 
ar
ea
 ra
tio
 2
7O
H
-C
ho
l/I
S 
A 
Spiked 27OHC (ng/mL)
 
 
 
 
 
 
 
 
 
 
 
 
0.00 
0.10 
0.20 
0.30 
0.40 
0.50 
0.60 
0 50 100 150 200 250 300 
B 
Spiked 27OHC (ng/mL)
C
or
re
ct
ed
 p
ea
k 
ar
ea
 ra
tio
 2
7O
H
-C
ho
l/I
S  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The addition of 27OHC standard solution to 100 L plasma (A) and 5-
times diluted 100 L plasma (B). Corrected peak area ratios were calculated by 
subtracting peak area ratio of the spiked plasma from the blank plasma. Peak 
area ratio is the response ratio of 27OHC to its deuterated internal standard. 
 
 
 Figure 6a, 6b and 7 altogether indicate several factors contributing to the variability in 
the 27OHC response. First, spiking the plasma on the top of a high endogenous level of the 
analyte, to construct a calibration curve, resulted in the non-linearity and large variation of the 
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analyte response. The second problem was the limited linear dynamic range of the method 
which did not allow spiking an even diluted plasma matrix. Therefore, we decided to 
substitute the matrix plasma with methanol for our calibrator standards so that less variability 
is introduced during the analysis. The recovery of spiked 27OHC from plasma (see section 
“Recovery” below) gave a result of near 100% (91% for 40 ng/mL and 98% for 100 ng/mL) 
enabling this matrix substitution. Furthermore, the ion suppression test confirmed that there 
was no suppression of the 27OHC response (tr ~10-11 min) when a methanolic 27OHC 
solution infused continuously during the injection of a plasma matrix sample (Figure 8). 
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Figure 7. Dilution of 100 L hydrolyzed plasma () and 50 L hydrolyzed plasma () 
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Figure 8. No ion suppression was observed during the 27OHC elution time (tr ~10-11 min) 
 
 
3.3.2. Method Validation 
The calibration curve was constructed using standard solution in methanol during the 
whole validation process. The concentration range of the calibration curve was 10 to 250 
ng/ml. The calibration curve was plotted as the peak area ratio of 27OHC to the internal 
standard vs. concentration. The calibration curve was linear and the least-square regression data 
(n=6) gave a regression line of y = 0.0103x – 0.0443 and a correlation coefficient of 0.9997. 
 In order to minimize the variability introduced during the analysis, the precision and 
accuracy of the method were confirmed in spiked, non-hydrolyzed and diluted plasma 
samples. Non-hydrolyzed plasma should only contain about 10-15% of the total endogenous 
27OHC since the rest is esterified with fatty acids(19, 21). The precision and accuracy of the 
method was checked in 50 L spiked diluted plasma and 15 L spiked diluted plasma. 
Because the aim of the method is to analyze the total endogenous 27OHC in undiluted plasma 
samples, the between-days precision was also confirmed in hydrolyzed undiluted plasma 
samples, as this will be the procedure used for real samples. The LOQ was determined as the 
concentration when the imprecision remained below 15%. Thus, the LOQ was 10 ng/ml and 
40 ng/ml for 50 L and 15 L samples, respectively. 
 The precision was defined as the coefficient of variation of the assayed concentrations. 
The accuracy was defined as the bias of the assayed concentration to the weight-in 
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concentration. The results are presented in Table 1. The chromatogram of 27OHC in a plasma 
sample is shown in Figure 9. 
 For the recovery test, defined amounts of 27OHC and the internal standards were 
added to plasma (samples) and to clean vials (standards) and analyzed as described in the 
“Experimental”. The recovery was determined by comparing the average peak areas of the 
samples to the peak areas of the standards. The recoveries for 27OHC were 91% (40 ng/ml) 
and 98% (100 ng/ml). The recoveries for the internal standard, 27OHC-d6, were 100% (40 
ng/ml) and 106% (100 ng/ml). 
 In comparison to the published LC-APCI-MS and GC-MS methods, the developed 
LC-MS method with DA-APPI is more sensitive, allowing the quantification of total 27OHC 
in plasma from a very low amount of sample (15 L). Further advantage is that no prior 
derivatization is needed, unlike the LC-ESI-MS or the long-established GC-MS method. The 
sensitivity achieved broadens the usefulness of the LC-MS method in experimental and 
clinical applications.  
 
Table 1: Precision and accuracy of 27OHC determination in plasma 
Diluted 
unhydrolyzed 
plasma 
Weight-in 
concentration 
(ng/ml) 
Replicates Mean 
(ng/ml) 
SD Precision 
(%) 
Accuracy 
(%) 
 
Within-day 
10 6 11.3 0.9 7.5 113.4 50 L 
40 6 36.4 1.6 4.5 90.9 
40 6 37.4 3.3 8.7 93.5 
125 6 136.2 17.7 13.0 108.9 
15 L 
200 6 222.2 19.67 8.9 111.1 
 
Between-days 
10 6 11.1 1.0 9.4 111.0 50 L 
40 6 39.7 3.9 9.9 99.3 
40 6 42.5 1.8 4.2 106.2 
125 6 125.4 2.8 2.2 100.3 
15 L 
200 6 205.2 15.7 7.7 102.6 
15 L hydrolyzed 
plasma  
- 6 254.7 27.9 10.9 - 
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 RT = 10.5
 
 
 
 
 
 
 
 
 
Figure 8. Chromatogram of an extracted plasma spiked with 40 ng/ml 
27OHC and analyzed in SIM mode for m/z 385.2. The LC-MS condition was 
as explained in the “Experimental” section. RT: retention time (min).  
 
 
3.4. Conclusions 
We have demonstrated that DA-APPI (Dopant Assisted - Atmospheric Pressure 
Photoionization) improves the sensitivity of 27OHC analysis, allowing quantification from 
very low sample amounts (50 L and 15 L plasma). Critical parameters were the dopant 
used and the flow rate of the dopant, as well as the solvent used as the LC eluent. The method 
has been validated and is ready to be used in various studies where the amount of sample is 
very limited, such as biomarker evaluation studies in animal models or lipoprotein subfraction.  
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Abstract 
Secretion of 27-hydroxycholesterol (27OHC) from macrophages has been proposed as an 
alternative mechanism to the high-density lipoprotein (HDL)-mediated reverse cholesterol 
transport. We therefore investigated 27OHC concentrations in plasma and lipoproteins of 
humans and mice with monogenic disorders of HDL metabolism. In humans, mutations in the 
genes encoding for apolipoprotein (apo) A-I, ATP binding cassette transporter A1 (ABCA1) 
and lecithin:cholesterol acyl transferase (LCAT) were associated with reduced concentrations 
of both HDL-cholesterol and HDL-27OHC; whereas mutations in cholesteryl ester transfer 
protein (CETP), scavenger receptor type B class 1 (SR-BI) and hepatic lipase (HL) were 
associated with elevated concentrations of HDL-27OHC and HDL-cholesterol. Likewise, 
plasma 27OHC were decreased in apoA-I and LCAT knockout mice and increased in SR-BI 
knock-out mice. Normalization for HDL-cholesterol revealed that mutations in LCAT caused 
less pronounced decreases of HDL-27OHC as compared to HDL-cholesterol. Moreover, 
LCAT activity appeared more strongly correlated with 27OHC-ester than to cholesteryl ester 
in HDL. The esterification of 27OHC appeared to be more sensitive to reduced LCAT activity 
than cholesterol esterification. Furthermore, 27OHC levels in apoB-containing lipoproteins 
were increased in LCAT or ABCA1, decreased in HL, and unaltered in mutation carriers of 
other HDL genes. In conclusion, mutations in several HDL genes led to distinct alterations in 
the quantity, esterification or lipoprotein distribution of 27OHC.   
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4.1. Introduction 
 27-Hydoxycholesterol (27OHC) is a metabolite of cholesterol formed by the 
mitochondrial cytochrome P450 sterol 27-hydroxylase (CYP27), an enzyme particularly 
expressed in the vascular endothelium, macrophages and the liver (1-4). Introduction of a 
hydroxyl group allows the otherwise hydrophobic cholesterol molecule to pass amphiphilic 
membranes more easily (5-6). Because of these physicochemical properties, 27OHC has been 
postulated to be secreted from cells independently of transporters and extracellular lipoprotein 
acceptors and thereby to facilitate an alternative route for apoA-I/HDL-mediated reverse 
transport of cholesterol from macrophages to the liver (7). In the liver, 27OHC is an important 
intermediary product of the so-called alternative bile acid synthesis pathway which 
contributes ~10% to de novo bile acid biosynthesis (4). Finally, 27OHC is an important 
activating ligand of liver-X-receptors (LXR), which are nuclear hormone receptors regulating 
the transcription of several genes involved in lipid and lipoprotein metabolism (8-9). 
 27OHC is the most abundant oxysterol (oxidized cholesterol) in the circulation (10)  
while plasma levels of 27OHC have been found to correlate with the cholesterol content in 
atherosclerotic lesions and the severity of coronary artery disease (11-13). Patients with 
genetic CYP27 deficiency suffer from cerebrotendinous xanthomatosis and develop 
premature atherosclerosis despite having normal levels of plasma cholesterol (14). Taken 
together, 27OHC has been proposed to be an anti-atherogenic molecule (1-2, 7, 15-17). 
Since the classical reverse cholesterol transport is mediated by high-density 
lipoproteins (HDL), and because HDLs are important carriers of 27OHC in plasma (18), we 
investigated whether monogenic disorders of HDL metabolism affect plasma and lipoprotein 
concentrations of 27OHC. We used an LC-MS method which allows to quantify 27OHC in 
very small plasma volumes (15-50 L) (19). Specifically, we analyzed plasmas of patients 
with functionally relevant mutations or mice with knock-outs of the following genes: 
apolipoprotein A-I (apoA-I) which is the main protein component of HDL; ATP-binding 
cassette transporter A1 (ABCA1) which mediates cholesterol and phospholipid efflux from 
cells to apoA-I; lecithin:cholesterol acyl transferase (LCAT) which esterifies cholesterol and 
thereby converts discoidal HDL precursors into mature spherical HDL particles; cholesteryl 
ester transfer protein (CETP, not expressed in mice) which exchanges cholesteryl ester of 
HDL against triglycerides of apoB-containing lipoproteins; scavenger receptor type B class 1 
(SR-BI) which mediates selective uptake of cholesterol esters into the liver and steroidogenic 
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organs; and hepatic lipase (HL, only in humans) which hydrolyses triglyceride and 
phospholipids in HDL (20). 
 
 
4.2. Methods 
4.2.1. Origin of Plasma Samples from Mice and Humans  
All animal procedures were approved by the Bioethical committee of the Biomedical 
Research Institute of the Academy of Athens. All animal experimentations were in agreement 
with the ethical recommendation of the European Communities Council Directive 
(86/609/EEC). Mutants as well as C57B/6 control mice were purchased from Jackson 
Laboratory (Bar Harbor, ME, USA) and maintained on standard chow diets containing 5% fat 
(Harlan Teklad, Madison, WI, USA). Mice were fasted for 6 hours before the collection of 
blood samples. Samples from mutants and wild-type control mice were collected in EDTA-
containing eppendorf tubes, kept in room temperature for 20 min and centrifuged to collect 
the plasma. All samples were stored in -80oC and transported in dry ice.  
Forty-one Dutch patients with functionally relevant mutations in the genes encoding 
for either LCAT, ABCA1, APOA1, SR-BI, CETP or HL as well as 41 unaffected family 
members were investigated.  Most of the families and the underlying defects were described 
previously (21-25). In addition, 4 Danish patients with mutations in apoA-I or CETP as well 
as 5 age- and sex-matched controls were included. The Medical Ethics Committee of the 
Academic Medical Center (AMC) in Amsterdam, The Netherlands, as well as the Danish 
Ethics Committee for Copenhagen and Frederiksberg, Denmark, approved all genetic and 
phenotypic studies described and all participants signed an informed consent to join the study.  
The characteristics of the study participants are shown in table 1. Fasting blood samples were 
collected after at least a 10-hours fast in the morning and EDTA-plasma was prepared through 
centrifugation of the blood at 3000 rpm for 10 min at 25C by the study nurses of the AMC, 
Amsterdam, The Netherlands, and of the Department of Clinical Biochemistry, 
Rigshospitalet, Copenhagen, Denmark.  Aliquots were immediately frozen at -80C until later 
use. 
 
 
Table 1.  Characteristic of the study participants. Values represent mean ± SD. 
Mutated 
gene 
Number of 
defective  
alleles 
Mutation# Age 
(year) 
Cholesterol 
(mM) 
HDL-cholesterol 
(mM) 
Non-HDL cholesterol 
(mM) 
Triglyceride 
(mM) 
Number  
of  
smokers 
DUTCH 
APOA-I 0  27 ± 14 4.59 ± 0.68 1.16 ± 0.06 3.43 ± 0.63 1.09 ± 0.29 0 
 1 p.L202P (c.605T>C) 26 ± 17 3.61 ± 0.31 0.51 ± 0.35 3.10 ± 0.06 1.09 ± 0.51 0 
ABCA1 0  44 ± 20 4.39 ± 0.89 1.47 ± 0.39 2.92 ± 0.62 0.95 ± 0.22 1 
 1 p.L1056P (c.3167T>C) or  p.C1477R 
(c.4429T>C) 
57 ± 11 4.47 ± 1.08 0.94 ± 0.17 3.53 ± 0.96 1.01 ± 0.05 0 
 2 p.L1056P (c.3167T>C, homozygote)  
or  p.Q1038X (c.3112C>T) + 
p.N1800H (c.5398A>C)  or  p.C1477R 
(c.4429T>C) + IVS25+1G>C 
53 ± 10 2.89 ± 2.39 0.10 / ND* 2.79 ± 2.39 2.29 ± 1.80 0 
LCAT 0  49 ± 9 4.96 ± 0.86 1.33 ± 0.38 3.62 ± 0.97 1.29 ± 0.66 0 
 1 p.T147I (c.440C>T), p.R322C 
(c.964C>T), p.N155D (c.463A>G), 
p.P34Q (c.101C>A), p.Y107X 
(c.321C>A), p.I202T (c.605T>C)  or 
p.V333M (c.997G>A) 
43 ± 13 4.27 ± 1.21 0.81 ± 0.28 3.45 ± 1.08 1.30 ± 0.55 1 
 2 p.T147I (c.440C>T) + V333M 69 ± 4 3.26 ± 0.19 0.14 ± 0.01 3.11 ± 0.20 2.11 ± 0.49 0 
SR-BI 0  54 ± 19 4.77 ± 0.89 1.17 ± 0.33 3.60 ± 0.79 1.21 ± 0.64 0 
 1 p.P297S (c.889C>T) 45 ± 22 4.46 ± 1.21 1.73 ± 0.56 2.73 ± 0.81 0.97 ± 0.28 1 
CETP 0  36 ± 16 4.14 ± 0.51 1.30 ± 0.21 2.85 ± 0.48 0.87 ± 0.40 1 
 1 IVS7+1 (G>T) 39 ± 18 4.20 ± 0.51 1.56 ± 0.29 2.64 ± 0.77 0.76 ± 0.32 1 
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Table 1.  (continued) 
Mutated 
gene 
Number of 
defective 
alleles 
Mutation Age 
(year) 
Cholesterol 
(mM) 
HDL cholesterol 
(mM) 
Non-HDL cholesterol 
(mM) 
Triglyceride 
(mM) 
Number  
of  
smokers 
HL (LIPC) 0  45 ± 19 5.23 ± 0.99 1.61 ± 0.54 3.62 ± 0.90 1.45 ± 1.05 3 
 1 p.S289F (c.866C>T) 45 ± 15 4.92 ± 1.21 2.00 ± 0.68 2.92 ± 0.86 1.14 ± 0.43 1 
DANISH 
Controls 0  50 ± 9 5.84 ± 1.24 1.54 ± 0.24 4.30 ± 1.23 1.34 ± 0.62 1 
APOA-I 1 p.L168R (c.503T>G) 63 ± 4 4.70 ± 0.28 0.85 ± 0.07 3.85 ± 0.35 1.27 ± 0.70 0 
CETP 1 p.S349Y (c.1046C>A) 59 ± 4 6.85 ± 2.05 3.05 ± 1.77 3.80 ± 0.28 0.86 ± 0.23 1 
* Either the detection limit of the assay or not detectable (ND) 
# Amino acid changes are localized on the basis of the entirely translated protein, that is including the signal peptides. To define the position within the mature 
protein, correct apoA-I by -24 amino acids, ABCA1 by -60 amino acids, LCAT by -24 amino acids, SR-BI by 0 amino acids, CETP by - 17 amino acids, HL by -
22 amino acids. 
 
 
 
4.2.2. Quantification of 27OHC  
The concentrations of 27OHC in total and apoB-depleted plasma were analyzed using 
dopant assisted-atmospheric pressure photoionization (DA-APPI) liquid chromatography-
mass spectrometry (LC-MS) method as described previously (26).  For the quantification of 
unesterified 27OHC, the hydrolysis step was omitted and the sample volume was increased to 
100 L due to the very low endogenous level of free 27OHC (only ~10-20% of total 27OHC) 
(18). 
For the determination of 27OHC in HDL, apoB-containing lipoproteins were removed 
from 100 L human EDTA plasma by precipitation with dextran-sulfate-Mg2+ (27). 27OHC 
concentrations assayed in apoB-depleted plasma were multiplied by 1.1 to correct for the 
dilution and to obtain the concentration of 27OHC in HDL. The difference between the 
concentrations of total 27OHC and HDL-27OHC is described as nonHDL-27OHC 
concentration.  We have shown previously that this method recovers about 95% of 27OHC in 
the apoB-depleted fraction, as compared to density-gradient ultracentrifugation, and that 
nearly 90% of plasma 27OHC is contained in the lipoprotein fractions (18). 
   
 
4.2.3. Quantification of Other Lipids, Apolipoproteins and LCAT  
Total plasma cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol levels 
were measured with commercial kits (Wako, Neuss, Germany and Randox, Crumlin, UK) on 
a Cobas Mira autoanalyzer. Plasma apoB, apoA-I, and apoA-IIs were measured with 
commercial assays (Randox). 
The unesterified cholesterol concentrations in the supernatant after precipitation of 
apoB-containing lipoproteins with polyethylenglycol (PEG) were assayed using a procedure 
that has been developed in house. Briefly, a mixture of reagent (200 L) containing 7.3 
mg/mL homovanilic acid, 0.1 M 3-[N-Morpholine]propanesulfonic acid, 1.25 mM 
taurocholate, 1.35 U/mL cholesterol oxidase and 10 U/mL peroxidase was added to 30 L 
sample and assayed using the FLUOstar Galaxy fluorometer (BMG Labtech, Offenburg, 
Germany). The assay was based on the reaction of cholesterol with oxygen to give hydrogen 
peroxide, which subsequently reacted with homovanilic acid to give a fluorescence emission 
at 450 nm wavelength. Cholesteryl ester concentrations were calculated as the differences of 
total and unesterified cholesterol concentrations.  
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LCAT activity and cholesterol esterification rates (CER) were determined using 
proteoliposomes containing radioactive cholesterol as the exogenous substrate assay and after 
equilibration of plasma with 3H-cholesterol as the endogenous substrate assay, respectively 
(28).  
 
 
4.2.4. Statistical Analysis 
Statistical analyses were performed using Microsoft Excel (Microsoft, Redmont, WA, 
USA) and SPSS 17.0 (SPSS, Chicago, IL, USA).  Normal distribution was tested using 
Kolmogorov-Smirnov test.  Since the data distribution was normal, unpaired student-t test 
was used to test for statistical significances of differences between two groups (assuming 
equal variance). Significance of a correlation was tested from the Pearson’s correlation 
coefficient (r).  
 
 
4.3. Results 
4.3.1. Effects of Gender, Age and Statin Treatment on 27OHC Levels in Humans 
Because of a strong effect of gender on plasma 27OHC levels (18), we stratified our 
data by sex. Because 27OHC concentrations in plasma are little affected by age (18), we did 
not further adjust the data for age. About 35% of all probands were treated with statins. 
However, when comparing family controls with and without statin treatment, this did not 
appear to affect plasma- and HDL- 27OHC concentrations: 0.47 ± 0.07 M vs. 0.50 ± 0.15 
M, and 0.20 ± 0.05 M vs. 0.23 ± 0.15 M, respectively. We therefore did not stratify the 
data for statin treatment.  
 
 
4.3.2. Effects of Inborn Errors of HDL Metabolism on 27OHC Levels  
In table 2, we compared the concentrations of 27OHC in total plasma, HDL and non-
HDL. As shown previously (18), we identified significant positive correlations between 
27OHC and cholesterol levels in total plasma, HDL and non-HDL fractions (see figure 1). 
These plots as well as the ratios of 27OHC to cholesterol (figure 1 and table 3) allowed us to 
identify those conditions in which 27OHC levels were altered beyond cholesterol levels. 
Homozygous defects in LCAT and ABCA1 were associated with significantly 
increased 27OHC/cholesterol ratios in plasma (table 3). All other differences were either not 
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statistically significant or not consistent: male but not female SR-BI mutation carriers showed 
lower 27OHC plasma levels as compared to all male controls, but not as compared to 
unaffected male relatives from the same family (table 2). The significantly decreased levels of 
27OHC plasma levels in male and female carriers of the apoA-I(p.L202P) mutant were not 
retrieved in individuals carrying the apoA-I(p.L168R) mutation (table 2).   
Defects in the genes of LCAT and ABCA1 were associated with gene-dosage-
dependent decreases of HDL-27OHC levels. Heterozygous carriers of apoA-I mutations also 
showed significantly decreased 27OHC levels in HDL. Conversely, defects that increase 
HDL-cholesterol levels also tended to increase HDL-27OHC levels (table 2 and figure 1B).  
However, this effect was statistically significant for only male CETP and HL mutation 
carriers. After normalization for HDL-cholesterol levels, only defects in LCAT showed 
consistent and statistically significant associations with increased HDL-27OHC/HDL-
cholesterol ratios (table 3).  
 
y = 0.08x + 0.12
r = 0.54, p≤0.0001
0.00
0.20
0.40
0.60
0.80
1.00
0.00 2.00 4.00 6.00 8.00 10.00
Total-cholesterol (mM)
To
ta
l-2
7O
H
C
 (µ
M
)
Controls (n=46)
LCAT het (n=12)
LCAT comp (n=2)
ABCA1 het (n=6)
ABCA1 hom/comp (n=3)
APOA-I het (n=5)
CETP het (n=5)
HL het (n=4)
SR-BI het (n=8)
Linear (Controls (n=46))
 
A
Figure 1. Plots of 27OHC vs. cholesterol concentrations in the plasma (A), HDL (B), and nonHDL (C) of 
individuals with mutations in HDL genes and their unaffected relatives. The Pearson correlation and 
regression have been calculated on data from all unaffected family members („Controls” of table 1 and 2). 
„Het” = heterozygous, „hom/comp” = homozygous / compound heterozygous. Please note the biases 
towards elevated 27OHC concentrations in the plasma, HDL and nonHDL of LCAT mutation carriers as 
well as the biases towards higher HDL-27OHC and lower nonHDL-27OHC concentrations in the carriers 
of HL mutations. 
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Figure 1. (continued)  
Finally, 27OHC levels and the ratio of 27OHC/cholesterol were gene-dose-
dependently increased in the nonHDL fractions of ABCA1 mutation carriers and female 
LCAT mutation carriers (table 2 and 3, figure 1C). By contrast, male heterozygotes for 
defects in apoA-I, SR-BI, CETP or HL had lower nonHDL-27OHC levels as compared to the 
unaffected male controls (table 2). In HL mutation carriers, nonHDL-27OHC levels and 
nonHDL-27OHC/nonHDL-cholesterol ratio were lower than in unaffected controls from 
either the same families or the entire population (table 3 and figure 1C). 
Table 2.  27OHC levels in plasma and lipoproteins in families with monogenic disturbances of HDL metabolism.  „Controls” = sum of all unaffected family 
members („0”), „0“ =  unaffected family members, „1“ = heterozygous mutation carriers, „2“ = homozygous or compound heterozygous mutation carriers. *, **, 
*** and #, ##, ### indicate statistically significant differences (p≤0.05, p≤0.01, p≤0.001, respectively) as compared to „0“ and „Controls”, respectively. 
Number of 
participants 
27OHC in total plasma 
(µM) 
27OHC in HDL 
(µM) 
27OHC in nonHDL 
(µM) 
Mutated gene Number of 
defective 
alleles Female Male Female Male Female Male Female Male 
Controls 0 21 24 0.43 ± 0.10 0.60 ± 0.14 0.24 ± 0.09 0.26 ± 0.08 0.19 ± 0.06 0.34 ± 0.11 
Defects causing decreased levels of HDL cholesterol 
APOA-I 0 6 2 0.42 ± 0.08 0.74 ± 0.18 0.21 ± 0.04 0.26 ± 0.04 0.21 ± 0.06 0.48 ± 0.14 
  p.L202P (c.605T>C) 1 2 1 0.26 ± 0.01 *# 0.33 # 0.10 ± 0.04 **# 0.06 # 0.16 ± 0.06 0.27 
  p.L168R (c.503T>G) 1 2 0 0.37 ± 0.06  0.14 ± 0.05 *  0.23 ± 0.01  
ABCA1 0 4 4 0.38 ± 0.09 0.50 ± 0.11 0.20 ± 0.04 0.23 ± 0.05 0.18 ± 0.05 0.27 ± 0.06 
 1 3 3 0.40 ± 0.03 0.58 ± 0.10 0.14 ± 0.02 0.18 ± 0.08 0.26 ± 0.05 0.40 ± 0.10 
 2 2 1 0.43 ± 0.40 0.51 0.06 ± 0.05 **## 0.01 *## 0.38 ± 0.35 ## 0.50 * 
LCAT 0 3 5 0.42 ± 0.04 0.64 ± 0.13 0.29 ± 0.06 0.27 ± 0.06 0.13 ± 0.03 0.36 ± 0.09 
 1 4 8 0.47 ± 0.15 0.56 ± 0.17 0.20 ± 0.01 * 0.22 ± 0.04 0.27 ± 0.16 0.34 ± 0.15 
 2 2 0 0.37 ± 0.07  0.04 ± 0.00 **##  0.32 ± 0.08 *##  
Defects causing increased levels of HDL cholesterol 
SR-BI 0 4 4 0.42 ± 0.11 0.55 ± 0.15 0.17 ± 0.06 0.19 ± 0.05 0.25 ± 0.06 0.37 ± 0.13 
 1 5 3 0.42 ± 0.09 0.41 ± 0.14 # 0.24 ± 0.04 0.22 ± 0.02 0.18 ± 0.09 0.19 ± 0.13 # 
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Table 2. (continued) 
Number of 
participants 
27OHC in total plasma 
(µM) 
27OHC in HDL 
(µM) 
27OHC in nonHDL 
(µM) 
Mutated gene Number of 
defective 
alleles Female Male Female Male Female Male Female Male 
CETP 0 5 3 0.43 ± 0.09 0.76 ± 0.17 0.22 ± 0.03  0.30 ± 0.06 0.20 ± 0.07 0.46 ± 0.12 
  (IVS7+1 (G>T)) 1 1 2 0.45 0.53 ± 0.08 0.25 0.33 ± 0.12 # 0.21 0.20 ± 0.04 
  p.S349Y(c.1046C>A) 1 1 1 0.49 0.72 0.26 0.45 # 0.22 0.27 
HL (LIPC) 0 3 7 0.51 ± 0.17 0.58 ± 0.12 0.36 ± 0.16 0.29 ± 0.10 0.15 ± 0.04 0.29 ± 0.11 
 1 1 3 0.52 0.53 ± 0.07 0.45 # 0.49 ± 0.08 **### 0.07 0.04 ± 0.04 **### 
 
 
Table 3.  27OHC/cholesterol ratios in plasma, HDL and non HDL of families with monogenic disturbances of HDL metabolism.  „Controls” = sum of all unaffected 
family members („0”), „0“ = unaffected family members, „1“ = heterozygous mutation carriers, „2“ = homozygous or compound heterozygous mutation carriers. *, 
**, *** and #, ##, ### indicate statistically significant differences (p≤0.05, p≤0.01, p≤0.001, respectively) as compared to „0“ and „Controls”, respectively. 
Ratio total-27OHC (µM) 
/ total-cholesterol (mM)  
Ratio HDL-27OHC (µM) 
/ HDL-cholesterol (mM) 
Ratio nonHDL-27OHC (µM) 
/ nonHDL-cholesterol (mM) 
Mutated gene Number of 
defective 
alleles Female Male Female Male Female Male 
Controls 0 0.09 ± 0.01 0.12 ± 0.02 0.15 ± 0.03 0.21 ± 0.04 0.06 ± 0.01 0.09 ± 0.03 
HDL Maturation 
APOA-I 0 0.08 ± 0.02 0.13 ± 0.01 0.15 ± 0.04 0.20 ± 0.01 0.06 ± 0.01 0.11 ± 0.01 
  p.S349Y (c.1046C>A) 1 0.07 ± 0.01 0.10 0.16 ± 0.02 0.31 # 0.05 ± 0.02 0.08 
  p.L168R (c.503T>G) 1 0.08 ± 0.02  0.16 ± 0.04  0.06 ± 0.01  
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Table 3. (continued) 
Ratio total-27OHC (µM) 
/ total-cholesterol (mM) 
Ratio HDL-27OHC (µM) 
/ HDL-cholesterol (mM) 
Ratio nonHDL-27OHC (µM) 
/ nonHDL-cholesterol (mM) 
Mutated gene Number of 
defective 
alleles Female Male Female Male Female Male 
ABCA1 0 0.08 ± 0.01 0.12 ± 0.01 0.12 ± 0.01 0.19 ± 0.02 0.06 ± 0.01 0.09 ± 0.01 
 1 0.11 ± 0.03 0.12 ± 0.02 0.16 ± 0.05 0.19 ± 0.07 0.09 ± 0.02 0.10 ± 0.02 
 2 0.11 ± 0.02 # 0.36 ***### 0.58 ± 0.46 ### 0.09 **## 0.10 ± 0.02 *### 0.39 ***### 
LCAT 0 0.09 ± 0.01 0.12 ± 0.02 0.17 ± 0.02 0.25 ± 0.05 0.05 ± 0.02 0.09 ± 0.02 
 1 0.11 ± 0.03 # 0.13 ± 0.02 0.22 ± 0.06 ### 0.33 ± 0.10 ### 0.08 ± 0.04 # 0.09 ± 0.02 
 2 0.11 ± 0.03 #  0.30 ± 0.03 **###  0.10 ± 0.03 ###  
HDL Catabolism 
SR-BI 0 0.08 ± 0.01 0.12 ± 0.04 0.13 ± 0.03 0.19 ± 0.01 0.07 ± 0.01 0.11 ± 0.05 
 1 0.09 ± 0.02 0.10 ± 0.02 0.12 ± 0.02 0.18 ± 0.06 0.07 ± 0.03 0.06 ± 0.04 
CETP 0 0.09 ± 0.02 0.14 ± 0.03 0.15 ± 0.03 0.22 ± 0.02 0.06 ± 0.02 0.12 ± 0.03 
  (IVS7+1 (G>T)) 1 0.12 0.12 ± 0.01 0.13 0.24 ± 0.08 0.12 ### 0.07 ± 0.02 
  p.S349Y (c.1046C>A) 1 0.09 0.09 0.15 0.10 *## 0.06 0.08 
HL (LIPC) 0 0.09 ± 0.02 0.11 ± 0.01 0.17 ± 0.04 0.21 ± 0.04 0.05 ± 0.00 0.07 ± 0.02 
 1 0.08 0.12 ± 0.04 0.15 0.30 ± 0.06 **### 0.02 *## 0.01 ± 0.02 **### 
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  4.3.3. Esterification of 27OHC in Patients with HDL Deficiency  
LCAT activity was decreased to about 75% of normal in female and male 
heterozygotes for LCAT defects (table 4). This decreased LCAT activity affected neither the 
esterification rate nor the cholesteryl ester/total cholesterol ratios in total plasma and HDL. By 
contrast, the percentage of 27OHC-ester was significantly decreased while the ratio of free-
27OHC/free-cholesterol was significantly increased in both plasma and HDL of heterozygous 
LCAT mutation carriers as compared to unaffected family members. A regression analysis 
revealed a stronger correlation of LCAT activity with 27OHC-ester concentration than with 
cholesteryl ester concentration in HDL (figure 2). Interestingly, the percentage of esterified 
27OHC was also significantly decreased in plasma and HDL of heterozygous apoA-
I(p.L202P) carriers, but not of heterozygotes for the apoA-I(p.L168R) mutation. No 
significant changes were observed in the degree of 27OHC esterification in carriers of 
ABCA1 defects.   
 
 
Table 4.  Esterification of 27OHC and cholesterol in plasma and lipoproteins of LCAT mutation carriers.  
* and *** indicate statistically significant differences (p≤0.05 and p≤0.001, respectively) between „1” and 
„0”. 
 Unaffected 
family 
members („0”) 
Heterozygous 
mutants („1”) 
Number (male/female) 5/3 8/4 
LCAT activity (nmol cholesteryl ester/hour*mL) 8.37 ± 1.21 6.58 ± 1.01 *** 
% 27OHC ester in plasma 92.3 ± 6.7 89.8 ± 4.3 
% cholesteryl ester in plasma 87.7 ± 2.4 88.4 ± 1.4 
Ratio 27OHC ester (µM) / cholesteryl ester (mM) in plasma  0.16 ± 0.04 0.16 ± 0.03 
Ratio unesterified 27OHC (µM) / unesterified cholesterol (mM) in plasma  0.09 ± 0.06 0.15 ± 0.08  
% 27OHC ester in HDL 88.4 ± 4.4 79.8 ± 10.6 * 
% cholesterol esters in HDL 80.9 ± 3.0 82.5 ± 3.6 
Ratio 27OHC ester (µM) / cholesteryl ester (mM) in HDL  0.22 ± 0.06  0.21 ± 0.07 
Ratio unesterified 27OHC (µM) / unesterified cholesterol (mM) in HDL  0.12 ± 0.04 0.28 ± 0.20 * 
% 27OHC ester in nonHDL 93.3 ± 23.9 95.8 ± 9.6 
% cholesterol esters in nonHDL 92.5 ± 1.4 91.4 ± 2.0 
Ratio 27OHC ester (µM) / cholesteryl ester (mM) in nonHDL  0.13 ± 0.06 0.14 ± 0.05 
Ratio unesterified 27OHC (µM) / unesterified cholesterol (mM) in nonHDL  0.14 ± 0.19 0.10 ± 0.10 
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Figure 2. Correlations of LCAT activities with the concentrations of 27OHC-
ester (A) and cholesteryl ester (B) in HDL in families with LCAT defects.  
 
 
 
4.3.4. 27OHC in Mice with Various Knock-outs of HDL Genes  
In normal murine plasma both cholesterol and 27OHC is almost exclusively carried by 
HDL (table 5). We therefore analyzed the different genetic mouse strains for total 27OHC 
plasma levels only. Compared to wild-type mice, apoA-I or LCAT knock-out mice were 
characterized by more than 50% lowered plasma 27OHC concentrations, whereas SR-BI 
knock-out mice had about 5-fold higher 27OHC levels. After normalization for total 
cholesterol, the differences remained statistically significant for LCAT and SR-BI knock-out 
mice only. In mouse plasmas, by contrast to HDL in human plasma, the ratio 27-
OHC/cholesterol was lowered rather than increased. In addition, ABCA1 deficient mice 
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showed an increased 27OHC/cholesterol ratio in the presence of normal 27OHC levels (table 
6).  
 
 
Table 5.  Comparison between the plasma and HDL concentrations of 27OHC and cholesterol in mice 
with knock-outs of apoA-I and SR-BI.  „+/+“ = wild-type controls, „+/-“ = heterozygous knockouts, „-/-“ = 
homozygous knockouts.   
27OHC concentration (µM) Cholesterol concentration (mM) Mutants Number of 
mice (n) plasma HDL plasma HDL 
+/+ 3 0.13 ± 0.04 0.10 ± 0.02 1.77 ± 0.35 1.67 ± 0.12 
APOA-I -/- 2 0.08 ± 0.00 0.07 ± 0.01 1.25 ± 0.35 1.15 ± 0.21 
SR-BI +/- 3 0.20 ± 0.06 0.20 ± 0.04 2.87 ± 0.06 2.17 ± 0.12 
SR-BI -/- 3 1.11 ± 0.12 1.08 ± 0.32 3.50 ± 0.26 3.13 ± 0.25 
 
 
 
Table 6.  27OHC plasma levels in mice with knock-outs of LCAT, apoA-I, ABCA1 or SR-BI.  „+/+“ = 
wild-type controls, „+/-“ = heterozygous knockouts, „-/-“ = homozygous knockouts.  *, **, *** indicate 
statistically significant differences (p≤0.05, p≤0.01, p≤0.001, respectively) as compared to „+/+“. 
Mutants Number of 
mice (n) 
27OHC in total 
plasma (µM) 
Ratio total-27OHC (µM) 
/ total-cholesterol (mM) 
+/+ 28 0.15 ± 0.08 0.08 ± 0.04 
APOA-I -/- 5 0.06 ± 0.04 * 0.05 ± 0.05 
ABCA1 +/- 3 0.08 ± 0.01 0.06 ± 0.02 
ABCA1 -/- 6 0.11 ± 0.06 0.19 ± 0.08 *** 
LCAT -/- 8 0.06 ± 0.02 ** 0.03 ± 0.01 *** 
SR-BI +/- 9 0.18 ± 0.04 0.06 ± 0.02 
SR-BI -/- 10 0.96 ± 0.32 *** 0.29 ± 0.10 *** 
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4.4. Discussion 
We have previously shown for normolipidemic individuals that about 50% and 30% of 
circulating 27OHC in healthy individuals is carried by HDL and LDL, respectively (18).  We 
also observed statistically significant correlations between concentrations of cholesterol and 
27OHC, which were stronger in total plasma (r = 0.54) and nonHDL (r = 0.72) than in HDL  
(r = 0.34) (18). In the present study these correlations were even stronger (figure 1). 
Following the strong correlation between HDL-cholesterol and HDL-27OHC (r = 0.64 in 
normolipidemic individuals of Dutch descent without any mutation in the HDL genes), 
functionally relevant mutations in apoA-I, ABCA1 and LCAT that decrease HDL-cholesterol 
were associated with reduced concentrations of 27OHC in HDL, whereas mutations in the 
genes of CETP, SR-BI and HL that increase HDL-cholesterol levels were associated with 
elevated HDL-27OHC concentrations. For defects in ABCA1 or LCAT, for which we could 
investigate the effects of both monoallelic and biallelic mutations, HDL-27OHC levels and 
HDL-cholesterol levels showed similar gene-dose-dependent alterations. Likewise, HDL 
deficient mice with knock-outs of apoA-I, ABCA1 or LCAT presented with decreased 
27OHC plasma levels. Conversely, 27OHC plasma levels were strongly elevated in SR-BI 
knock-out mice, which are hypercholesterolemic.  
Taken together, in humans and mice with inborn errors of HDL metabolism, HDL-
27OHC levels appeared simply to change passively in parallel with HDL-cholesterol levels. 
However, normalization of HDL-27OHC levels for HDL-cholesterol levels revealed that loss 
of LCAT function is an interesting exception. In both genders, mutations in LCAT caused 
(dose-dependently) relatively less pronounced decreases in HDL-27OHC than HDL-
cholesterol levels in comparison with unaffected family members and the entire mutation-free 
control population as well as other genetic low HDL conditions. This happened although 
reduced LCAT activity has a stronger impact on 27OHC-ester formation than on cholesteryl 
ester formation. Thus, as it has been shown previously (18) as well as in this study, the 
proportion of 27OHC-esters is higher than the proportion of cholesteryl esters in both plasma 
and HDL (table 4). Moreover, heterozygous LCAT mutation carriers showed reduced 
27OHC-ester/total-27OHC ratios, but normal cholesteryl ester/total cholesterol ratios, in 
HDL. Finally, LCAT activity showed a stronger correlation with 27OHC-ester concentrations 
than with cholesteryl ester concentrations in HDL (figure 2). This observational data do not 
allow any conclusion on the biochemical basis for these differences. One reason may be 
differences in the reaction kinetics (affinity and/or maximal reaction velocity) of LCAT 
towards 27OHC and cholesterol, so that reduced LCAT activity in mutation carriers affects 
  83
27OHC esterification more strongly than cholesterol esterification. Alternatively, 
esterification of 27OHC may depend more strictly on LCAT than cholesterol, for example 
because it is not esterified by acyl-CoA:cholesterol acyl transferase (ACAT) (29-30).  
However, since 27OHC-ester/total-27OHC ratio was decreased in HDL but not in apoB-
containing lipoproteins of LCAT mutation carriers, and since ACAT is especially relevant for 
the secretion of cholesteryl esters in apoB containing lipoproteins (30), the former explanation 
is more likely than the latter one. In any case, it is important to emphasize that the elevated 
27OHC/cholesterol ratio in LCAT mutation carriers is the result of a relatively high 
concentration of unesterified 27OHC, rather than of esterified 27OHC. It thus appears that 
reduced LCAT activity increases the capacity of HDL particles to accommodate unesterified 
27OHC.  
Another interesting finding was the counter-reactive increase of 27OHC levels in the 
non-HDL fraction. It was most prominent in HDL deficient individuals in that compound 
heterozygosity for mutations in LCAT or ABCA1 showed increased concentrations of 
27OHC, both in absolute concentrations and relative to cholesterol, in non-HDL fraction, that 
is apoB-containing lipoproteins. Vice versa, heterozygous carriers of HL mutations presented 
with strongly decreased 27OHC concentrations in the nonHDL fraction, both in absolute 
concentrations and relative to cholesterol. It hence appears that the changes in HDL particle 
numbers or composition due to mutations in LCAT, ABCA1 and HL result in a redistribution 
of 27OHC among lipoproteins. In this regard, it is important to emphasize that the plasma 
concentration of 27OHC (0.5 mol/L in average), unlike the concentration of cholesterol      
(5 mmol/L in average), is considerably lower than the particle concentration of both HDL 
(about 20 mol/L in average) and LDL (about 2 mol/L in average). Therefore, and also 
because of its higher water-solubility (6), 27OHC may passively equilibrate among the 
various lipoprotein fractions.  
It has been suggested that HDL-independent 27OHC secretion represents an 
alternative pathway to HDL-mediated cholesterol efflux by which macrophages protect 
themselves from cholesterol overload (1-2, 7, 15-17). This observational study does not 
provide conclusive arguments either in support or in contradiction to this concept. On the one 
hand, the strong correlation between HDL-cholesterol and HDL-27OHC in normolipidemic 
population as well as the parallel changes of HDL-cholesterol and HDL-27OHC observed in 
this study rather contradicts the concept of an HDL-independent reverse cholesterol transport 
pathway. On the other hand, neither in humans nor in mice ABCA1 deficiency had any effect 
on 27OHC levels. Rather by contrast, 27OHC/cholesterol ratios were increased in the plasma 
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of both ABCA1 knock-out mice and humans with two defective ABCA1 alleles, which may 
be taken as indirect indication that 27OHC is secreted independently from ABCA1.  
In conclusion, in most cases, defects in HDL metabolism affect 27OHC concentrations 
in HDL to a similar degree as cholesterol in this lipoprotein. The most important exception 
were mutations in LCAT, possibly because reduced LCAT activity impairs 27OHC 
esterification in the plasma compartment more pronouncedly than cholesterol esterification. 
In addition, several defects in HDL metabolism led to counter-reactive changes of 27OHC 
levels in apoB-containing lipoproteins, which were not observed for cholesterol. Finally, our 
data in humans and mice with inborn errors of HDL metabolism neither support nor 
contradict the concept that 27OHC represents an HDL-independent mode of reverse 
cholesterol transport. 
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Abstract 
Approximately 60% of plasma sphingosine-1-phosphate (S1P) is carried by high density 
lipoproteins (HDL) and contributes to several beneficial cardiovascular effects of HDL. To 
explore whether HDL-cholesterol levels determine S1P levels in plasma, we analyzed S1P 
levels in total and apoB-depleted plasmas of 48 patients with monogenic disorders of HDL 
metabolism as well as in their 51 unaffected relatives. Compared to unaffected family 
members, S1P levels in total and apoB-depleted plasma were significantly decreased in 
hypoalphalipoproteinemic individuals with mutations in apoA-I (heterozygotes: -23% and      
-29%, respectively), ABCA1 (heterozygotes: -37% and -45%, respectively;  compound 
heterozygotes: -64% and -79%, respectively), or LCAT (heterozygotes: -32% and -22%, 
respectively; homozygotes: -53% and -62%, respectively). No difference was found when 
comparing the heterozygotes for the mutations in CETP, SR-BI or HL (which have high 
HDL-cholesterol levels) with their unaffected relatives. In addition, the regression analyses of 
data from all individuals without mutations revealed statistically significant correlations 
between S1P levels and HDL-cholesterol levels if apoA-I levels were in the lowest tertile 
(<1.48 g/L), which became weaker and statistically insignificant as apoA-I levels increased. 
Finally, the infusion of reconstituted HDL (rHDL) into the heterozygous mutation carriers of 
apoA-I or LCAT increased plasma S1P levels in vivo. We concluded that the plasma levels of 
HDL-cholesterol and apoA-I determined plasma S1P concentrations, but only at the lower 
end of the distribution curve.  
  90
5.1. Introduction 
Sphingosine-1-phosphate (S1P) is produced by the degradation of ceramides into 
sphingosine which is subsequently phosphorylated by sphingosine kinase (1). As the ligand of 
at least five different G-protein coupled receptors, S1P exerts many biological activities (2). 
Recently, erythrocytes have been established as the main source (~90%) of plasma S1P (3). 
Platelets and endothelial cells are considered as important contributors for the remaining 
~10% of S1P found in plasma (4-6). 
Published plasma S1P concentrations varied from ~200 nM up to ~2000 nM (7-9). 
The S1P levels in blood and body fluids are 20 to 100 fold higher than the Kd values of its 
receptors (8, 10, 11). Circulating S1P is transported by high-density lipoproteins (HDL, ~50-
70%), albumin (~30%), low and very-low density lipoproteins (LDL and VLDL, respectively; 
together <10%). Because of approximately 10 to 20 fold lower particle numbers, however, 
each LDL particle carries more S1P than each HDL particle (>50 mmol/mol and <10 
mmol/mol, respectively) (8, 11-14). 
The S1P carried by HDL has been thought responsible for the many cardioprotective 
effects of this lipoprotein class (8, 14-16). For example, HDL-S1P inhibits the migration of 
vascular smooth muscle cells (VSMCs), promotes vasodilation by stimulating endothelial 
nitric oxide synthase (eNOS) and thereby nitric oxide production, and promotes endothelial 
cell growth and survival by inducing cell proliferation, migration, and tube formation as well 
as by inhibiting apoptosis and reactive oxidative species (ROS) production. In addition, HDL-
S1P interferes with the recruitment of monocytes and lymphocytes into the intima of the 
arterial wall by inhibiting the endothelial cell expression of vascular cell adhesion molecule-1 
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in response to TNF-. By 
contrast, intracellular S1P appears to exert adverse effects such as stimulating the expression 
of VCAM-1 and ICAM-1, mediating the pro-inflammatory effects of cytokines, and inducing 
vasoconstriction (8, 14, 16, 17). 
To date, little is known on the determinants of S1P levels in plasma. Since the main 
portion of S1P has been reported to be carried by HDL, the effects of plasma HDL levels on 
plasma S1P concentration was studied. Specifically, the S1P levels in total and apoB-depleted 
plasmas of patients with functional mutations in the following genes were investigated: 
apolipoprotein A-I (apoA-I), which is the main protein component of HDL; ATP-binding 
cassette transporter A1 (ABCA1), which mediates cholesterol and phospholipid efflux from 
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cells to apoA-I; lecithin:cholesterol acyl transferase (LCAT), which esterifies cholesterol and 
thereby converts nascent HDL into mature HDL; cholesteryl ester transfer protein (CETP), 
which exchanges cholesteryl ester from HDL with triglycerides from apoB-containing 
lipoproteins; scavenger receptor type B class 1 (SR-BI), which mediates selective uptake of 
cholesteryl esters into the liver and steroidogenic organs; hepatic lipase (HL), which 
hydrolyses triglyceride and phospholipids in HDL; and endothelial lipase (EL), which 
preferentially hydrolyses HDL-phospholipids (18, 19). HDL-cholesterol levels are low in 
patients with mutations in either apoA-I, ABCA1 or LCAT and elevated in patients with 
mutations in either CETP, SR-BI, HL or EL. Since we found S1P levels to be modulated by 
low HDL levels, but not by high HDL levels, we also tested the effects of infusing 
reconstituted HDL (rHDL) on S1P levels in patients with apoA-I and LCAT mutations. 
 
 
5.2. Methods 
5.2.1. Subjects and Sample Collection 
Forty-eight Dutch patients with functional mutations in the genes encoding for either 
LCAT, ABCA1, apoA-I, SR-BI, CETP, HL or EL as well as 51 unaffected family members 
were investigated. Most of the respective defects have been described previously (20-29). 
Mutations that have not yet been reported for ABCA1 are c.3167T>C (p.L1056P), c.3112C>T 
(p.Q1038X), and c.5398A>C (p.N1800H), the homozygosity for p.L1056P and the compound 
heterozygosity for p.Q1038X and p.N1800H (paper submitted). The as yet undescribed 
p.R322C mutation caused 38% loss on the LCAT activity when analyzed using a 
proteoliposome substrate assay. A frameshift mutation in LIPG was anticipated to be 
functional since the deletion resulted in a premature truncation of the enzyme 
(p.L130fsX165).  
The Medial Ethics Committee of the Academic Medical Center in Amsterdam, The 
Netherlands, approved all the genetic and phenotypic studies described and all participants 
signed informed consents to join the study. The characteristics of the study participants are 
shown in table 1. Fasting blood samples were collected after at least a 10-hour fast in the 
morning and EDTA-plasma was prepared through centrifugation of the blood at 3000 rpm for 
10 min at 25C. Aliquots were immediately frozen at -80 degrees until later use. 
 
Table 1. Characteristics of the study participants. Values are presented as mean ± SD. The apolipoprotein levels in mg/dL were converted into M based on apoA-I, 
apoB-100 and dimeric apoA-II molecular weights (28’300, 512’000 and 17’400 Da, respectively). 
Mutated 
gene 
Number of 
defective 
alleles 
Mutation Age 
(year) 
Cholesterol 
(mM) 
HDL- 
cholesterol 
(mM) 
Triglyceride 
(mM) 
ApoA-I 
(M) 
ApoB 
(M) 
ApoA-II 
(M) 
ApoA-I 0  27 ± 14 4.59 ± 0.68 1.16 ± 0.06 1.09 ± 0.29 57.57 ± 4.68 1.89 ±  0.30 16.96 ± 0.64 
 1 p.L202P (c.605T>C) 26 ± 17 3.61 ± 0.31 0.51 ± 0.35 1.09 ± 0.51 30.64 ± 13.52 1.67 ± 0.13 10.77 ± 3.71 
ABCA1 0  44 ± 20 4.39 ± 0.89 1.47 ± 0.39 0.95 ± 0.22 56.44 ± 10.18 1.64 ± 0.24 17.35 ± 2.02 
 1 p.L1056P (c.3167T>C) or  p.C1477R (c.4429T>C) 57 ± 11 4.47 ± 1.08 0.94 ± 0.17 1.01 ± 0.05 43.68 ± 4.17 1.92 ± 0.43 15.89 ± 1.15 
 2 
p.L1056P (c.3167T>C, 
homozygote)  or  p.Q1038X 
(c.3112C>T) + p.N1800H 
(c.5398A>C)  or  p.C1477R 
(c.4429T>C) + IVS25+1G>C 
53 ± 10 2.89 ± 2.39 0.10 / ND* 2.29 ± 1.80 1.53 ± 0.88 2.27 ± 1.29 0.43 ± 0.75 
LCAT 0  49 ± 9 4.96 ± 0.86 1.33 ± 0.38 1.29 ± 0.66 60.24 ± 7.63 1.84 ± 0.47 17.75 ± 1.18 
 1 
p.T147I (c.440C>T), p.R322C 
(c.964C>T), p.N155D 
(c.463A>G), p.P34Q (c.101C>A), 
p.Y107X (c.321C>A), p.I202T 
(c.605T>C)  or p.V333M 
(c.997G>A) 
43 ± 13 4.27 ± 1.21 0.81 ± 0.28 1.30 ± 0.55 43.26 ± 9.71 1.90 ± 0.56 15.12 ± 2.78 
 2 p.T147I (c.440C>T) + V333M 69 ± 4 3.26 ± 0.19 0.14 ± 0.01 2.11 ± 0.49 18.50 ± 1.22 1.74 ± 0.38 2.15 ± 0.13 
SR-BI 0  54 ± 19 4.77 ± 0.89 1.17 ± 0.33 1.21 ± 0.64 51.43 ± 7.62 1.74 ± 0.36 15.78 ± 1.50 
 1 p.P297S (c.889C>T) 45 ± 22 4.46 ± 1.21 1.73 ± 0.56 0.97 ± 0.28 65.04 ± 11.67 1.34 ± 0.34 18.96 ± 3.06 
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Table 1. (continued) 
Mutated 
gene 
Number of 
defective 
alleles 
Mutation Age 
(year) 
Cholesterol 
(mM) 
HDL- 
cholesterol 
(mM) 
Triglyceride 
(mM) 
ApoA-I 
(M) 
ApoB 
(M) 
ApoA-II 
(M) 
CETP 0  36 ± 16 4.14 ± 0.51 1.30 ± 0.21 0.87 ± 0.40 56.69 ± 5.25 1.52 ± 0.26 17.29 ± 0.89 
 1 IVS7+1 (G>T) 39 ± 18 4.20 ± 0.51 1.56 ± 0.29 0.76 ± 0.32 59.56 ± 4.47 1.45 ± 0.28 15.67 ± 2.47 
HL (LIPC) 0  45 ± 19 5.23 ± 0.99 1.61 ± 0.54 1.45 ± 1.05 56.67 ± 10.89 2.51 ± 0.48  
 1 p.S289F (c.866C>T) 45 ± 15 4.92 ± 1.21 2.00 ± 0.68 1.14 ± 0.43 71.03 ± 20.49 2.06 ± 0.45  
EL (LIPG) 0  41 ± 21 5.43 ± 1.24 1.82 ± 0.50 0.74 ± 0.27 61.66 ± 14.03 1.64 ± 0.46  
 1 
p.L130fsX165 (premature stop) or 
p.R476W 45 ± 21 
5.41 ± 1.23 1.83 ± 0.51 1.37 ± 0.82 63.01 ± 16.67 1.86 ± 0.47  
* Either the detection limit of the assay or not detectable (ND) 
# Amino acid changes are localized on the basis of the entirely translated protein, that is including the signal peptides. To define the position within the mature 
protein, correct apoA-I by -24 amino acids, ABCA1 by -60 amino acids, LCAT by -24 amino acids, SR-BI by 0 amino acids, CETP by - 17 amino acids, HL by 
-22 amino acids, EL by 0 amino acids. 
 
 
 
5.2.2. Infusion of rHDL 
One 29 years old female patient with fish-eye disease (a compound heterozygous for 
p.T147I and p.V333M), one 42 years old female patient with Tangier disease (a homozygous 
for p.L1056P), two heterozygotes for mutations in apoA-I (p.L202P; male, 61 years old) or 
LCAT (male, 56 years old), as well as one 57 years old male control received an infusion of 
rHDL (ZLB Behring, Bern, Switzerland) at a dose of 40 mg/kg body weight over a period of 
3 hours (30). Blood was drawn at baseline (Pre) and 7 days (Day = 7) thereafter and S1P 
levels were analyzed.   
 
 
5.2.3. Lipoprotein Fractionation  
Lipoproteins were isolated from pooled plasmas of two healthy blood donors (Zürcher 
Blutspendedienst, Zurich, Switzerland) by stepwise ultracentrifugation at 59’000 rpm and 
15C using a Beckman Coulter Optima L90K ultracentrifuge (Beckman Coulter, Brea, CA, 
USA) (31). 
For some measurements, apoB-containing lipoproteins were removed from 100 L 
EDTA plasma by precipitation with dextran-sulfate-Mg2+ (0.9 g/L dextran sulfate and 45 
mmol/L Mg2+ as the final concentration after being added to the sample) (32). The S1P 
concentration in the LDL/VLDL fraction was calculated by subtracting the S1P levels 
measured in apoB-depleted-plasma from the S1P levels measured in total plasma. 
 
 
5.2.4. Sample Preparation 
Samples were prepared by protein precipitation without any further lipid extraction.  
An aliquot of 25 L EDTA plasma or apoB-depleted plasma as well as 25 L, 1.09 nM, 
internal standard (IS) solution in methanol (C17-S1P; Avanti Polar Lipids, Alabaster, AL, 
USA) were added to 200 L methanol. The mixture was vortexed immediately each time after 
the addition of methanolic solution to plasma to minimize anisotropic precipitation. The 
mixture was then centrifuged at 10’000x g for 10 min at 4C (Centrifuge 5415R, Vaudaux-
Eppendorf, Schönenbuch, Switzerland). The precipitated proteins were discarded and 5 L of 
the supernatant was directly injected into the LC-MS system. 
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5.2.5. Blanks, Calibration and Quality Control (QC)  
To prepare S1P-free plasma for blanks, calibrators, and quality control (QC) matrix, 
activated charcoal was added to EDTA plasma from a healthy volunteer (100 mg charcoal per 
mL plasma) and mixed for at least 12 hr. The mixture was then centrifuged (10’000x g, 15 
min at room temperature) a few times until the supernatant was clear. Charcoal and the bound 
S1P were removed from the supernatant by sequential passaging through filters with 0.45 m 
and 0.22 m pore diameters. 
S1P (Avanti Polar Lipids, Alabaster, AL, USA) was dissolved in DMSO:concentrated-
HCl (100:2 by volume) to make 0.28 µM stock solutions. Standards were prepared by further 
dilution of the stock solution in methanol (0.06, 0.14, 0.28, 0.57, 1.42, 2.27 nM). 
The standards (25 L), IS (25 L) and methanol (175 L) were added to the charcoal-
treated plasma (25 L) and processed as described in “Sample Preparation” above. A 
calibration curve was constructed by plotting the peak area ratios of S1P/IS and the 
concentrations of the S1P standards. The S1P concentration in samples was derived from the 
S1P/IS peak area ratios relative to the calibration curve. The calibration curve was obtained 
for each series of samples which was analyzed within one day.  
Two quality controls were prepared using S1P standards in methanol (0.45 and 1.14 
nM) and assayed at the beginning and at the end of each sample series. Blank samples 
(blanks) were prepared by adding the IS (25 L) to the charcoal-treated plasma (25 L) and 
methanol (200 L), then processed as in “Sample Preparation”. Blanks were assayed before 
each run of the calibrators and samples for the purpose of baseline correction and to correct 
for any carryover in the system. 
 
 
5.2.6. Liquid Chromatography – Mass Spectrometry (LC-MS) 
 The LC-MS system consisted of an HTC PAL autosampler (CTC Analytics, 
Zwingen, Switzerland) with cooled sample trays (4C), a Rheos 2000 HPLC pump (Flux 
Instruments, Basel, Switzerland) and a TSQ Quantum Ultra mass spectrometer (Thermo 
Fisher Scientific, Waltham, MA, USA). The chromatographic conditions for the reversed-
phase separation of S1P have been modified from Schmidt H et al (33). We used a Nucleosil 
C18 HD column (125x2 mm, 100 Å, 5 m) which was connected to a Nucleosil C18 HD 
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guard column (8x4 mm, 100 Å, 5 m) and heated at 30C with a HotDog 5090 column oven 
(Prolab Instruments, Reinach, Switzerland). The mobile phase A was a mixture of 
methanol/tetrahydrofuran/0.1% formic acid (2/2/3) and the mobile phase B was a mixture of 
methanol/tetrahydrofuran (1/1). Gradient elution was performed always at 200 L/min flow 
rate and started with 100% mobile phase A for the first 0.6 min. The mobile phase B was 
subsequently increased to 100% within 4.4 min, then kept constant for 4 min. The column 
was then re-equilibrated with 100% mobile phase A for 15.5 min. The S1P and IS eluted at tr 
~7.7 min.  
 The carryover of S1P from the injection system was minimized by washing the 
syringe and the injector valve 12 times with a mixture of methanol/acetone/isopropanol 
(1/1/1) containing 0.1% formic acid and 3 times with a mixture of acetone/methanol/water 
(2/2/1) after each injection. In addition, the column was flushed with methanol at least twice 
after each sample run. The column was also flushed with a mixture of 
methanol/aceton/isopropanol (1/1/1) after an injection of highly concentrated samples or 
calibrators to further minimize the carryover of S1P from the column. 
 The ionization of S1P was performed using electrospray ionization (ESI). The 
detection was conducted in the positive mode, monitoring [M+H]+ ions using selective 
reaction monitoring (SRM) for the transition of m/z 380.2  264.2 (16 V, 1 mTorr) for the 
target analyte (S1P) and m/z 366.2  82.06 (34 V, 1 mTorr) for the IS. The MS parameters 
were as follow: 5000 V spray voltage, 10 V skimmer offset, and 150C ion-transfer capillary 
temperature. Further parameters were optimized by tuning the system with S1P standards. 
The data analysis was performed on XCalibur 2.0.7 SP1 software. 
 
 
5.2.7. Statistical Analysis 
Statistical analyses were performed using Microsoft Excel (Microsoft, Redmont, WA, 
USA) and SPSS 17.0 (SPSS, Chicago, IL, USA). Normal distribution was tested using 
Kolmogorov-Smirnov test. Since the distribution was normal, unpaired student-t test was used 
to test statistical significances for the differences between two groups (assuming equal 
variance). Significance of a correlation was tested from the Pearson’s correlation coefficient 
(r).  
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5.3. Results 
5.3.1. Analytical Method Validation 
 Before analyzing samples, the newly established LC-MS method was validated. 
Recoveries of 105.7% and 103.7% were obtained for charcoal-treated plasma spiked with 
0.14 M and 0.57 µM S1P, respectively, suggesting the binding of endogenous S1P to 
proteins was completely disrupted during protein precipitation. At 0.06 M, 0.14 M and 
0.57 µM concentrations, the intra-day imprecision amounted to 10.9%, 1.8% and 6.3%, 
respectively, and the inter-day imprecision to 10.2%, 8.2% and 3.9%, respectively. At the 
same concentrations, the intra-day accuracy amounted to 111.3%, 98.5% and 100.9%, 
respectively, and the inter-day accuracy to 103.2%, 92.35% and 95.2%, respectively. 
 
 
5.3.2. Lipoprotein Distribution of S1P in Normolipidemic Blood Donors 
In line with the published literature (34, 35), nearly 60% of circulating S1P in plasma 
was recovered in HDL. Nearly 30% of plasma S1P was recovered in the lipoprotein-depleted 
fraction (LPDS). S1P in LDL and triglyceride-rich lipoproteins (chylomicrons and VLDL) 
accounted for only 8.1% and 3.3%, respectively. After precipitation of apoB-containing 
lipoproteins with dextran-sulfate-Mg2+, 85.3% S1P instead of 88.5% S1P expected from the 
ultracentrifugation data was recovered in the supernatant (containing S1P in HDL and LPDS).  
 
 
5.3.3. Plasma S1P Levels in Normolipidemic Individuals  
 In the entire sub-cohorts of relatives without any mutation in the HDL genes, the 
plasma levels of S1P amounted to 0.89 ± 0.34 M, of which 73.1 ± 9.9% could not be 
precipitated together with the apoB-containing lipoproteins. When comparing men (n = 26) 
and women (n = 25), there were no significant difference in the S1P concentrations in either 
plasma (0.83 ± 0.34 M vs. 0.86 ± 0.35 M), the supernatant after precipitation of apoB-
containing lipoproteins (0.60 ± 0.31 M vs. 0.60 ± 0.29 M) or the LDL/VLDL-fraction (0.26 
± 0.12 M vs. 0.26 ± 0.12 M). Regression analyses showed the absence of correlations 
between age and S1P levels in total (r = 0.0768) or apoB-depleted plasma (r = 0.1113). These 
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results allowed us to compare S1P levels of patients with disorders in HDL metabolism and 
normolipidemic controls without any stratification for age or gender.  
 
 
5.3.4. Plasma S1P Levels in Patients with Inborn Errors of HDL Metabolism 
 As shown in table 2, significantly decreased S1P plasma levels were observed in 
patients with low HDL-cholesterol levels due to mutations in LCAT, ABCA1 or apoA-I. The 
absence of HDL in the compound heterozygotes for mutations in LCAT or ABCA1 showed 
the most prominent decreases in S1P plasma levels (-50% and -65%, respectively). The 20 to 
30% decreased S1P plasma concentrations of the heterozygotes for apoA-I or ABCA1 
mutations as well as the 65% decreased S1P levels of the compound heterozygotes for 
ABCA1 mutations were exclusively explained by the decreases in S1P levels in the apoB-
depleted fractions. After normalization for HDL-cholesterol or apoA-I levels, S1P levels did 
not differ between the controls and the heterozygous carriers of mutations in LCAT or 
ABCA1 (table 2). However, the heterozygous carriers of apoA-I mutation as well as the 
compound heterozygotes for LCAT or ABCA1 mutations had significantly elevated ratios of 
S1P to HDL-cholesterol and apoA-I in the apoB-free plasma (table 2).  
Interestingly, both the heterozygotes and compound heterozygotes for LCAT 
mutations also showed decreased S1P levels in both apoB-containing and apoB-depleted 
fractions of plasma. Also, after normalization for the plasma levels of apoB or nonHDL-
cholesterol, carriers of LCAT mutations, but not carriers of other mutations, differed from 
their unaffected relatives by decreased S1P concentrations in apoB-containing lipoproteins 
(table 2). 
 
 
Table 2. S1P in patients with monogenic disturbances of HDL metabolism.  „Controls” = all unaffected relatives, „0“ =  unaffected relatives from specific mutation, 
„1“ = heterozygous mutant carriers, „2“ = homozygous or compound heterozygous mutant carriers. *, **, *** and #, ##, ### indicate statistically significant 
differences (p≤0.05, p≤0.01, p≤0.001, respectively) as compared to „0“ and „Controls”, respectively. 
Number of 
participants 
S1P in apoB-depleted fraction  S1P in LDL/VLDL fraction  Mutated 
gene 
Number 
of 
defective 
alleles Female Male 
S1P in total 
plasma (M) 
(M) per mM       
HDL- 
cholesterol 
per M apoA-I (M) per mM 
nonHDL- 
cholesterol 
per M apoB 
Controls 0 25 26 0.89 ± 0.34 0.65 ± 0.29 0.48 ± 0.23 0.012 ± 0.006 0.26 ± 0.12 0.08 ± 0.04 0.15 ± 0.08 
Defects affecting HDL maturation 
ApoA-I 0 1 2 1.13 ± 0.11 0.84 ± 0.02 0.73 ± 0.04 0.015 ± 0.002 0.29 ± 0.12 0.08 ± 0.03 0.15 ± 0.04 
 1 1 2 0.87 ± 0.13 0.60 ± 0.03 *** 1.66 ± 1.15 ### 0.022 ± 0.010 ## 0.27 ± 0.14 0.09 ± 0.04 0.16 ± 0.07 
ABCA1 0 4 4 1.38 ± 0.41 1.04 ± 0.44 0.75 ± 0.30 0.019 ± 0.009 0.34 ± 0.21 0.11 ± 0.06 0.20 ± 0.10 
 1 3 3 0.87 ± 0.29 * 0.57 ± 0.15 * 0.65 ± 0.25 0.013 ± 0.004 0.29 ± 0.21 0.08 ± 0.04 0.15 ± 0.07 
 2 1 2 0.50 ± 0.14 ** 0.22 ± 0.05 ** 2.17 ± 0.49 ***### 
0.168 ± 0.069 
***### 0.29 ± 0.13 0.12 ± 0.04 0.13 ± 0.01 
LCAT 0 5 3 0.69 ± 0.17 0.42 ± 0.12 0.34 ± 0.14 0.007 ± 0.002 0.27 ± 0.08 0.08 ± 0.02 0.15 ± 0.04 
 1 8 4 0.47 ± 0.12 **### 
0.33 ± 0.06 
*### 0.44 ± 0.14 0.008 ± 0.002 
0.15 ± 0.06 
***## 
0.05 ± 0.02 
**## 
0.08 ± 0.05 
**## 
 2 0 2 0.33 ± 0.002 *## 0.16 ± 0.00 **# 
1.15 ± 0.12 
***### 0.009 ± 0.001 0.17 ± 0.00 0.05 ± 0.00 0.10 ± 0.02 
Defects affecting HDL catabolism 
SR-BI 0 4 5 0.82 ± 0.06 0.59 ± 0.05 0.55 ± 0.21 0.012 ± 0.002 0.23 ± 0.06 0.07 ± 0.02 0.14 ± 0.04 
 1 3 4 0.90 ± 0.16  0.69 ± 0.16 0.44 ± 0.16 0.011 ± 0.003 0.22 ± 0.09 0.08 ± 0.03 0.16 ± 0.06 
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Table 2. (continued) 
Number of 
participants 
S1P in apoB-depleted fraction  S1P in LDL/VLDL fraction  Mutated 
gene 
Number 
of 
defective 
alleles Female Male 
S1P in total 
plasma (M) 
(M) per mM   
HDL- 
cholesterol 
per M apoA-I (M) per mM 
nonHDL- 
cholesterol 
per M apoB 
CETP 0 2 1 1.02 ± 0.13 0.59 ± 0.08 0.47 ± 0.13 0.011 ± 0.002 0.42 ± 0.09 0.15 ± 0.03 0.28 ± 0.05 
 1 2 1 1.03 ± 0.15 0.60 ± 0.03 0.40 ± 0.08 0.010 ± 0.001 0.43 ± 0.18 0.19 ± 0.14 ### 0.32 ± 0.20 ### 
HL  0 7 3 0.67 ± 0.18 0.51 ± 0.17 0.33 ± 0.10 0.009 ± 0.002 0.16 ± 0.05 0.05 ± 0.02 0.07 ± 0.03 
 1 3 1 0.68 ± 0.13 0.48 ± 0.14 0.27 ± 0.13 0.007 ± 0.003 0.19 ± 0.04 0.07 ± 0.03 0.10 ± 0.03 
EL  0 3 7 0.94 ± 0.24 0.69 ± 0.21 0.40 ± 0.16 0.013 ± 0.006 0.26 ± 0.06 0.08 ± 0.03 0.17 ± 0.05 
 1 6 4 0.85 ± 0.26 0.62 ± 0.21 0.40 ± 0.23 0.011 ± 0.006 0.22 ± 0.07 0.07 ± 0.03 0.12 ± 0.03 
 
 
 
 
 
 
 
 
Patients with mutations in SRB1, CETP, HL or EL, who have increased HDL-
cholesterol levels, remarkably did not show any statistically significant difference in S1P 
levels in either total or apoB-depleted plasmas. Normalization for HDL-cholesterol or apoA-I 
levels revealed no significant difference as well (table 2).  
 
 
5.3.5. Correlations of S1P Levels with Other Lipid Parameters in Family Members 
without any Mutation in the HDL Genes 
  Univariate regression analyses of data from 51 mutation-free family controls revealed 
inverse correlations between apoB-depleted-S1P levels with the concentrations of total 
cholesterol, nonHDL-cholesterol and apoB as the only ones with statistical significance. 
Interestingly, S1P levels in total plasma or apoB-free plasma did not correlate significantly 
with the plasma concentrations of HDL-cholesterol or apoA-I. Also of note, we did not find 
any significant correlation of S1P levels in apoB-containing lipoproteins with nonHDL-
cholesterol or apoB levels (table 3).  
 
Table 3.  Regression analyses of all cohorts of non-mutation carriers. Value represents 
correlation coefficient (r).  * and ** indicate statistically significant Pearson’s correlation 
coefficient (p≤0.05 and p≤0.01, respectively). 
 Total-S1P ApoB-depleted-S1P LDL/VLDL-S1P 
Total cholesterol -0.1949 -0.2811 * 0.0934 
HDL-cholesterol 0.1414 0.0316 -0.0689 
NonHDL-cholesterol -0.2366 -0.3225 ** 0.1353 
ApoA-I 0.0447 -0.1342 0.0327 
ApoA-I + ApoA-II 0.0775 -0.0447 0.2324 
ApoB -0.2683  -0.2966 * 0.0837 
 
 
Since S1P levels were reduced in individuals with low HDL-cholesterol and not 
increased in individuals with high HDL-cholesterol, we tested the hypothesis that HDL limits 
S1P levels only up to a certain threshold concentration and repeated the regression analyses in 
the sub-cohorts of non-mutation carriers who were stratified by apoA-I tertiles (figure 1).  The 
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subgroup of individuals with apoA-I levels in the lowest tertile (that is: <52.5 M or <1.48 
g/L, figure 1A) showed statistically significant correlations of S1P levels with HDL-
cholesterol and apoA-I, respectively. These correlations became weaker and statistically 
insignificant in individuals with apoA-I levels in the second (52.5-61.3 M or 1.48-1.74 g/L, 
figure 1B) or third (>62.3 M or >1.74 g/L, figure 1C) tertiles. Accordingly, we identified a 
statistically significant correlation between LDL/VLDL-S1P and apoA-I only in the lowest 
apoA-I tertile (figure 1D). 
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Figure 1.  Regression analyses of sub-cohorts of non-mutation carriers who were stratified by tertiles of 
apoA-I. 
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5.3.6. Effect of rHDL Infusion on S1P Levels  
The findings of both the low S1P levels in the hypolaphalipoproteinemic patients with 
inborn errors of HDL metabolism and the significant correlation of S1P levels with HDL-
cholesterol levels in the mutation-free controls with apoA-I levels <1.48 g/L suggested that a 
low HDL level limits the abundance of S1P in plasma. We therefore investigated the effect of 
rHDL infusion on S1P plasma levels in patients with familial low HDL-cholesterol levels as 
compared to control. In all patients, except for the compound heterozygote for LCAT 
mutations, S1P levels in total and apoB-depleted plasma (figure 2) increased in response to 
rHDL infusion and stayed higher than baseline for at least one week. 
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Figure 2. Changes in S1P levels after infusion of rHDL in 
patients with familial low HDL-cholesterol. 
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6.4. Discussion 
Plasma concentration of S1P varied widely among normolipidemic individuals, for 
example from 0.49 M to 1.21 M in the Dutch population of 47 family members without 
any mutations in the HDL genes. As yet, the determinants of S1P plasma concentrations have 
not been well explored. One obvious candidate is the plasma concentration of HDL, which 
induces S1P efflux from erythrocytes (34, figure 3) and carries about 60% of S1P in normal 
plasma. In fact, Zhang et al have previously reported very strong correlations between S1P 
levels with HDL-cholesterol (r = 0.82) or apoA-I levels (r = 0.91) (9). In contrast to these 
previous observations in a relatively small group of Japanese individuals (n = 16), we 
observed a more complex relationship between HDL and S1P levels.  
By investigating S1P levels in about 50 Dutch individuals with defined monogenic 
errors of HDL metabolism and approximately 50 unaffected family members, we found that 
the previous observations were only true for those individuals with relatively low plasma 
concentrations of HDL-cholesterol or apoA-I. Mutations in the genes of apoA-I, ABCA1 or 
LCAT decreased the plasma concentrations of HDL-cholesterol, apoA-I and S1P in gene-
dose-dependent fashions. The lowest S1P levels were found in patients with HDL deficiency 
due to two mutated ABCA1 or LCAT alleles. Specifically, they presented with 30 and 50% of 
normal S1P levels in total plasma or 20 and 40% of normal S1P levels in apoB-depleted 
plasma, respectively. By contrast, mutations in CETP, SR-BI, EL or HL, which increase 
HDL-cholesterol and apoA-I levels, did not affect S1P levels in either total or apoB-depleted 
plasma. 
Furthermore, in the subgroup of individuals without any mutation in one of the HDL 
genes, S1P levels in total or apoB-depleted plasma correlated significantly with HDL-
cholesterol levels only in individuals who presented with apoA-I levels in the lowest tertile, 
that is below 1.48 g/L. The correlations of S1P levels with HDL-cholesterol levels weakened 
and diminished with the increasing apoA-I or HDL-cholesterol tertiles.  
We made further observation that low HDL levels are the limiting factor for S1P 
plasma levels by an additional experiment. In vivo, infusion of rHDL increased S1P levels 
more profoundly in the heterozygotes for apoA-I or LCAT mutations than in a 
normolipidemic individual.  
Our finding that the low plasma concentrations of HDL might limit plasma S1P levels 
has been in agreement with the fact that the concentration of S1P is nearly 100-fold and 
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10’000-fold lower than those of apoA-I and HDL, respectively. Assuming that every HDL 
particle contains 2 to 4 apoA-I molecules, only 2 to 5% of HDL particles in normal plasma 
will transport one S1P molecule in average. Thus, even the heterozygosity for HDL-
deficiency syndromes, which are characterized by approximately half-normal levels of HDL-
cholesterol or apoA-I, should not limit the abundance of S1P in plasma. Our contrary finding 
suggested that S1P has been transported by specific HDL subclasses which were critically 
lowered in patients with low HDL-cholesterol. In fact, Kontush et al reported that in 
normolipidemic subjects, S1P is preferentially enriched in small dense HDL3 particles, rather 
than in large HDL2 particles (36). Interestingly, mutations in CETP, EL, HL and SR-BI 
increase the concentrations of HDL2 particles more pronouncedly than of HDL3 particles 
(37), which may explain the missing effect of mutations in these genes on S1P levels. It will 
be hence interesting to investigate the molecular determinants of S1P uptake and/or transport 
by specific HDL subclasses.  
About 10% of S1P in normolipidemic plasma is transported by LDL and VLDL. 
Similar to HDL, the concentration of S1P in LDL and VLDL (about 0.2 M) is about 10-fold 
lower than the concentration of apoB-containing particles (about 2 M).  Zhang and 
colleagues have previously reported a strong correlation between the S1P levels in LDL with 
the plasma levels of LDL cholesterol or apoB (9). In our study, however, we did not observe 
any statistically significant correlation between S1P levels in apoB-containing lipoproteins 
with the plasma concentrations of apoB or nonHDL-cholesterol. Rather by contrast, in 
individuals with apoA-I levels in the lowest tertile, we observed an inverse correlation of S1P 
levels with apoB or total cholesterol concentrations as well as of S1P levels in the 
LDL/VLDL fraction with apoA-I concentrations. Similar to the positive correlations between 
HDL-cholesterol and S1P in total or apoB-depleted plasma, these inverse correlations became 
weaker and finally disappeared with the increasing tertiles of apoA-I levels. These inverse 
relationships indicated an interaction of HDL particles and apoB-containing lipoproteins, by 
which in individuals with the low levels of HDL-cholesterol or apoA-I, S1P was shifted to 
apoB-containing lipoproteins and partially lost from the plasma compartment. Despite this 
interaction in normolipidemic relatives of mutation carriers, only defects in the LCAT gene 
influenced S1P levels in apoB-containing lipoproteins such that the S1P levels in VLDL and 
LDL were lower in homozygous or heterozygous mutant carriers than in unaffected family 
members.  
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In conclusion, we confirmed in this study that HDL carried about 60% of S1P in 
normal plasma. Although only ≤5% of HDL particles carry one S1P molecule, both mildly 
and severely lowered HDL concentrations due to multifactorial reasons or mutations in the 
genes of apoA-I, ABCA1 or LCAT limited the quantity of S1P in plasma. By contrast, high 
concentrations of HDL-cholesterol and apoA-I, neither because of mutations in the genes of 
CETP, SR-BI, EL or HL nor because of multifactorial reasons, influenced S1P levels in 
plasma. Since S1P exerts several anti-atherogenic functions of HDL, these findings have 
agreed with the concept of a threshold concentration of HDL or apoA-I which is needed for 
atheroprotection (38).  
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Abstract 
Sphingolipids and phospholipids are ubiquitous lipid groups encompassing more than 1000 
different lipid species. Their structural heterogeneity makes the profiling of sphingo- and 
phospholipids a challenge. We developed an LC-MS/MS method for the analysis of 
sphingomyelins (SM), phosphatidylglycerols (PG), phosphatidylethanolamines (PE), 
phosphatidic acids (PA), phosphatidylinositols (PI), phosphatidylserines (PS) and 
phosphatidylcholines (PC). Different lipid classes were separated based on their head-group 
rentention on a diol silica-based HPLC column. Parent-ion scanning was applied both for 
screening each lipid species and for the selectivity of the class determination. The feasibility 
of the method has been shown by analyzing plasma of patients with stable coronary heart 
diseases, allowing the analysis of both the total endogenous amount of lipids within the same 
class as well as the concentration of each lipid species within a given class.  
 
 
 
6.1. Introduction 
Sphingolipids and phospholipids are ubiquitous lipid groups encompassing more than 
1000 different lipid species. They function as essential building blocks of cell membranes and 
lipoproteins. They also act as first and second messengers in mediating cell-cell recognition 
and interaction (1). Despite their great functional diversities, sphingo- and phospholipids have 
been rarely investigated for their pathogenetic contribution to diseases or exploited for 
diagnostic purposes. 
Sphingo- and phospholipids are characterized by a sphingoid backbone and a 
glycerophosphate group, respectively (figure 1). Variation in their head groups determines 
their lipid classes. Each lipid class comprises at least 20 different lipid species, which differ in 
the number of carbons and double bonds of the fatty-acid tails (2-3).  
 
 
 
 
 113
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
sphingoid backbone
fatty acid
polar 
head 
group
SPHINGOLIPIDS
PHOSPHOLIPIDS
R =    H
 
 
 
Figure 1. Sphingolipid and phospholipid structures 
Ceramides (Cer)
Sphingomyelins (SM)
R3 =   H
polar 
head 
group
R1, R2 = fatty acyls
Phosphatidic acids (PA)
Phosphatidylcholines (PC)
Phosphatidylethanolamines (PE)
Phosphatidylgylcerols (PG)
Phosphatidylserines (PS)
Phosphatidylinositols (PI)
 114
Due to their structural heterogeneity, profiling of sphingo- and phospholipids is a 
challenge. Amongst the many efforts to achieve this, one interesting approach is the so-called 
“shotgun lipidomics”. Principally an intra-source separation and selective ionization of 
phospholipids and their lithium adducts (4-5), shotgun lipidomics offers sensitivity and the 
efficiency of single parent-ion scan on a triple quadrupole mass spectrometer. The method 
utilizes a syringe infusion for less than 30 min run-time and omits any chromatographic 
separation step. Ion suppression of the low abundance lipids, however, is one of the 
weaknesses. Another major drawback is contamination of the instrument with lithium ions 
(5). 
Separation with normal or reverse phase HPLC has been commonly applied to reduce 
the complexity of the lipids prior to mass spectrometric analysis and to minimize the risk of 
ion suppression. Various LC-MS/MS-based methods have been developed; for example, 
parent-ion or neutral-loss scans under data-dependent acquisition control on a hybrid Q-TOF 
(6-10), product-ion or parent-ion scan-dependent multiple reaction monitoring (MRM) on a 
Q-Trap (11-12), or linear trap/FT-ICR(13) and MS(n) on an Orbitrap mass analyzer (14-16). 
The LIPID MAPS Consortium (www.lipidmaps.org), for example, has been developing 
standard protocols based on product-ion scans and MRM for cataloguing lipid species in 
mammalian cells (12, 17).  
For the purpose of non-targeted analysis of sphingo- and phospholipids in a relatively 
large amount of samples, we developed an LC-MS/MS method combining HPLC separation 
with multiple parent-ion scans on a triple quadrupole mass spectrometer. The different lipid 
classes (sphingomyelins (SM), phosphatidylglycerols (PG), phosphatidylethanolamines (PE), 
phosphatidic acids (PA), phosphatidylinositols (PI), phosphatidylserines (PS) and 
phosphatidylcholines (PC)) were separated based on their polar head group retention on 
normal phase HPLC. Parent-ion scanning was applied both for screening each lipid species 
and for the selectivity of the class determination. The feasibility of the method has been 
shown by applying the method to analyze plasmas of patients with stable coronary heart 
diseases.  
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6.2. Materials and Methods 
6.2.1. Chemicals and Reagents 
Sphingo- and phospholipid standards (PG(17:0/17:0), PG(17:1/0:0), PE(17:0/17:0), 
PE(17:1/0:0), PA(17:0/17:0), PA(17:0/0:0),  PC(17:0/17:0), PC(17:0/0:0), PS(17:0/17:0), 
PI(12:0/13:0), PI14:0/17:0), L--PI (bovine liver), C17- sphingosine-1-phosphate (C17-S1P), 
SM(d18:1/6:0), SM(d18:1/6:0), SM(d18:1/12:0), Cer(d18:1/17:0)) were obtained from Avanti 
Polar Lipids (Alabaster, AL, USA). All solvents were of HPLC grade except for methyl-tert 
butyl ether, which was of pro analysis grade. Methanol, hexane and isopropanol were 
obtained from SDS (Cedex, France). Chloroform, n-butanol and methyl-tert butyl ether were 
obtained from Sigma Aldrich (Saint Louis, MO, USA). Citric acid and disodium phosphate 
were obtained from Sigma-Aldrich (Saint Louis, MO, USA). 
 
 
6.2.2. Lipid Nomenclature 
Lipid names were abbreviated according to the newly updated nomenclature used by 
the LIPID MAPS Consortium (18), where “headgroup(sn1/sn2)’ format  is used to describe a 
species with one or two radyl side-chains without specifying their stereochemistry (by default, 
attachment of head groups at sn3 position is assumed). Numbers between parentheses 
describe the side-chain structures, with the number before the colon refers to the number of 
carbons, while the number after the colon refers to the number of double bonds. For 
examples: PC(16:0/16:0) refers to 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine, 
PC(16:0/0:0) refers to 1-hexadecanoyl-sn-glycero-3-phosphocholine. Monoacyl species are 
also termed “lyso-“.   
For sphingolipids, the sn1 position refers to the typical sphingolipid backbone. For 
example, SM(d18:1/6:0) refers to sphingomyelins with sphingosine or 2-amino-4-octadecene-
1,3-diol as the backbone (‘d’ denotes the ‘double’ hydroxyl group attachment) and 6 carbon 
chain as the fatty-acid tail.  
In case of undifferentiated fatty-acid tails as in ‘Feasibility studies in patients and 
healthy volunteers’, the sum of the carbon and double bond numbers of the two acyl side-
chains was given. For example: PC(32:0) refers to any structural combination of two fatty-
acid tails (either PC(16:0/16:0) or PC(18:0/14:0) or PC(14:0/18:0), and so on), that together 
have 32 carbon atoms and 0 double bonds. 
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6.2.3. Plasma Samples  
Blood samples from two female and one male patients (67 ± 9 years old) with stable 
coronary heart diseases as well as 3 healthy female volunteers (29 ± 2 years old) were 
collected and EDTA-plasma was obtained by centrifugation at 1350x g for 10 min at 25C 
(Universal 32R, Hettich Zentrifugen, Tuttlingen, Germany). Samples were stored at -80C 
until use. 
 
 
6.2.4. Sample Pre-treatment 
6.2.4.1. Liquid-liquid Extraction for Sample Pre-treatment Optimization 
Different extraction methods using different solvents were compared. Liquid-liquid 
extraction of 100 µL sample was conducted using either methanol-chloroform as in the Bligh 
and Dyer extraction method (19), methyl-tert butyl ether (MTBE) (20), n-butanol (21) or a 
mixture of MTBE and n-butanol as in “Optimized liquid-liquid extraction for sample 
analysis”. The internal standard (IS) mixture solution contained 10 µg/mL each of 
PC(17:0/17:0), PC(17:0/0:0), C17-S1P, SM(d18:1/6:0), and Cer(d18:1/17:0). 
For the Bligh and Dyer procedure, 250 µL methanol, 125 µL chloroform and 10 L IS 
mixture solution were added to 100 µL sample. The mixture was sonicated for 10 s. 
Additional 100 µL water and 125 µL chloroform were added. The mixture was shaken for 15 
min and centrifuged at 1272x g for 5 min at 25C with Sigma 4-15 (Sigma Laborzentrifugen, 
Osterode am Harz, Germany). The lower phase was collected and additional 250 µL 
chloroform was added. The mixture was again shaken for 15 min and centrifuged at 1272x g 
for 5 min at 25C. All lower phases were combined.  
For the extraction procedure using MTBE solvent, 750 µL methanol, 2.5 mL MTBE 
and 10 L IS mixture solution were added to 100 µL sample. The mixture was shaken for 1 
hr. Additional 625 µL water was added and the mixture was shaken again for 10 min. The 
mixture was centrifuged at 1272x g for 5 min at 25C using Sigma 4-15 centrifuge. The upper 
phase was collected and the lower phase was re-extracted with 1 mL mixture of 
MTBE/methanol/water (10:3:2.5, v/v/v). All upper phases were combined.  
For the extraction procedure using n-butanol solvent, 300 µL buffer (containing 30 
mM citric acid and 40 mM disodium phosphate, pH 4), 2 mL n-butanol, 1 mL water-saturated 
n-butanol and 10 L IS mixture solution were added to 100 µL sample. The mixture was 
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shaken for 15 min and centrifuged at 1272x g for 5 min at 25C using Sigma 4-15 centrifuge. 
The upper phase was collected.  
The collected lower or upper phases from each of the extraction procedures were dried 
by evaporation at 45°C (Rotavapor, Büchi, Flawil, Switzerland). The residue was 
reconstituted in 100 L mobile phase mixture (70% hexane and 30% mixture of 
isopropanol:methanol:1% ammonium hydroxide (75:22.5:2.5)) and 10 L was injected into 
the LC-MS system. 
 
 
6.2.4.1. Optimized Liquid-liquid Extraction for Sample Analysis 
Extraction with a solvent mixture of MTBE and water-saturated n-butanol (80:20 by 
volume) was conducted as follows: 400 µL solvent mixtures and 10 L IS mixture solution 
were added to 100 µL sample. The mixtures were always shaken for 15 min and centrifuged 
at 1272x g for 5 min at 25C using Sigma 4-15 centrifuge. The procedure was repeated 3 
times with water-saturated n-butanol used for the third re-extraction. All upper phases were 
combined and dried by evaporation at 45°C (Rotavapor, Büchi, Flawil, Switzerland). The 
residue was reconstituted in 100 L mobile phase mixture (70% hexane and 30% mixture of 
isopropanol:methanol:1% ammonium hydroxide (75:22.5:2.5)) and 10 L was injected into 
the LC-MS system. 
The IS mixture solution contained 10 µg/mL each of PG(17:0/17:0), PG(17:1/0:0), 
PE(17:0/17:0), PE(17:1/0:0), PA(17:0/17:0), PA(17:0/0:0),  PC(17:0/17:0), PC(17:0/0:0), 
PS(17:0/17:0), PI(12:0/13:0) or PI14:0/17:0), and SM(d18:1/6:0) or SM(d18:1/12:0).   
 
 
6.2.5. LC-MS/MS 
The LC-MS system consisted of a Rheos 2000 pump (Flux Instruments, Basel, 
Switzerland), an HTC PAL autosampler (CTC Analytics, Zwingen, Switzerland) and a TSQ 
Quantum Ultra triple quadrupole mass analyzer (Thermo Fisher Scientific, Waltham, MA, 
USA). 
Normal phase HPLC separation was conducted on a diol silica-based column (QS 
Uptisphere 6 OH, 150 x 2.1 mm, 5 m). Mobile phase composition was 70% hexane and 30% 
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mixture of isopropanol:methanol:1% ammonium hydroxide (75:22.5:2.5). Elution was 
performed isocratically at a flow of 200 µL/min for 60 min.  
The MS parameters were set as follows: 4000 V spray voltage, 36 V skimmer voltage, 
250°C capillary temperature, and 30 and 5 (arbitrary) sheath and auxiliary gas, respectively. 
Tube lens voltages were tuned using a standard mixture of PG(16:0/0:0), PG(16:0/16:0), 
PA(16:0/16:0) and L--PI (bovine liver), covering a wide molecular mass range. Both Q1 and 
Q3 resolution were set at 0.7 peak-width (at full-width half-maximum). Multiple parent-ion 
scan events with polarity switching were performed using 0.5 mTorr collision gas (figure 2). 
Acquired data was analyzed using the Xcalibur software (version 2.0.7 SP1). 
 
 
6.2.6. Data Extraction 
 From each scan event, a mass-peak list containing parent-ion masses (m/z) and their 
intensities were generated using Xcalibur. The noise cut-off was determined by visually 
examining the mass spectra. The mass-peak list was entered to an online lipid database 
(www.lipidmaps.org) using a mass tolerance of ±0.5 Da. The database search output gave 
both the lipid classes and species, listing all possible combinations of fatty-acid tails. 
However, individual fatty-acid tail structure could have been obtained only by product-ion 
scans in the negative mode; hence only the sum of carbon and double bond numbers in the 
side-chains could be determined. All data were processed manually using Microsoft Excel 
(Microsoft, Redmont, WA, USA).  
Parent-ion scanning of m/z 153 was selective for glycerophospholipids, hence the 
database search output might give more than one possible phospholipid class. Other 
parameters (nitrogen rule, retention time, and ionization efficiency) were then considered for 
the lipid identification. Subsequently, a shortened list of tentative sphingo- and phospholipid 
species was generated, listing the determined lipid classes, each species with summed number 
of carbons and double bonds of the side chains, the observed masses (m/z), the absolute 
intensities, and intensities relative to the corresponding IS (each class has a non-endogenous 
(mono- and) diacyl lipid species as IS, see “Sample pre-treatment”). Comparison between 
samples was conducted based on the ratio intensity to the IS of the same tentative lipid 
species with the same parent mass (m/z). 
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6.3. Results and Discussions 
6.3.1. Sample Pre-treatment Optimization 
 Sphingo- and phospholipids differ in chemical and physical characteristics and interact 
with other endogenous compounds such as proteins (for example: lipoproteins). Hence, the 
quantitative extraction of all sphingo- and phospholipids was a challenge. Various solvents or 
solvent combinations have been suggested for extracting lipids from specific matrices (22-
25). However, many analysts generally used the “standard” Folch procedure (26) and its 
Bligh-and-Dyer (BD) variation (19) which utilize chloroform-methanol and the matrix’s 
water in a ternary system. 
 
Table 1. Comparison of different solvent and procedures for liquid-liquid extraction of several lipids from 
plasma. 
Extraction recovery from plasma (%) Lipid 
class 
Standards 
BD MTBE n-Butanol MTBE/n-Butanol 
Cer Cer(d18:1/17:0) 82.0 17.3 5.5 73.5 
SM SM(d18:1/6:0) 84.3 18.5 95.5 95.2 
PC PC(17:0/17:0) 95.8 82.2 100.9 84.0 
LPC PC(17:0/0:0) 86.6 50.9 101.3 96.1 
S1P C17-S1P 65.5 27.3 44.5 114.5 
 
 
Since chloroform is very toxic, we investigated other solvent combinations for liquid-
liquid extraction of lipids from plasma. We initially tested standards from 5 different lipid 
classes covering a wide range of different polarities (Cer, SM, PC, LPC and S1P: see figure 
1). When available, internal standards have been chosen from non-endogenous lipids which 
have odd-numbered fatty-acid chains. As shown in table 1, re-extraction of methyl-tert butyl 
ether (MTBE) extract with water-saturated n-butanol increased the extraction recovery of the 
more polar lipids. Improvement of the extraction recovery of highly polar lipids by re-
extraction with water-saturated n-butanol after a Folch procedure has also been shown in 
another published method (27). Thus, MTBE/n-butanol was used as the extraction solvent for 
sample analyses as it gave acceptable recoveries (>80%) for all the lipid classes in the text-
mixture, except for Cer. However, Cer was later excluded from this current ESI method to be 
profiled using a different APCI method since the ionization efficiency of Cer in APCI was 10 
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times higher than in ESI. Table 2 shows the extraction recoveries of the IS used for sphingo- 
and phospholipid profiling.  
 
Table 2. Extraction recoveries of different sphingo- and phospholipid classes 
Lipid class Internal standards Extraction recovery 
from plasma (%) 
PG(17:0/17:0) 94.0 PG 
PG(17:1/0:0) 82.5 
PE(17:0/17:0) 103.6 PE 
PE(17:0/0:0) 95.1 
PA(17:0/17:0) 82.3 PA 
PA(17:0/0:0) 90.5 
PS PS(17:0/17:0) 102.2 
PI PI(17:0/14:1) 89.4 
PC(17:0/17:0) 95.4 PC 
PC(17:0/0:0) 104.8 
SM SM(d18:1/6:0) 82.9 
 
 
 
6.3.2. Separation with Normal Phase HPLC  
 Sphingo- and phospholipids consist of two different moieties: the apolar fatty-acid 
tails and the head group which determines their lipid classes. The separation of sphingo- and 
phospholipid classes requires normal phase chromatography since the polar head groups 
should be retained on the silica column material. Resolution, however, was difficult to 
optimize due to the small differences in the molecular structures between classes (data not 
shown). Moreover, each lipid class can comprise more than 20 lipid species, with 16 to 26 
carbon chains from each of the fatty-acid tails plus their variation in the number of double 
bonds and hydroxyl groups, giving the heterogeneity in the molecular weights carried within 
each class. This and the fact that basic moieties tend to be adsorbed to the silica column 
material caused peak tailing and broadening and further decrease in the resolution of some 
lipid classes. The use of a diol silica-based column gave a better resolution than a normal 
silica column under the chromatographic condition as described in “LC-MS/MS” (data not 
shown). Further optimization of the separation by changing chromatographic conditions 
(solvent, solvent composition, pH, gradient elution) or by using either a combination of 2 
different columns (a normal silica column and a diol column) or a hydrophilic interaction 
chromatography (HILIC) column did not give satisfactory results (data not shown). Finally, 
the HPLC method was developed on the diol silica-based column under the condition as 
described in “LC-MS/MS” (figure 2). 
 
*** ***
0 5 10 15 20 25 30 35 40 45 50 55
Time (min)
0
50
100
0
50
100
0
50
100
0
50
100
R
el
at
iv
e 
A
bu
nd
an
ce
0
50
100
0
50
100
BP: 720.76
721.12 720.64 719.60 721.32720.16 721.88720.20 719.44721.08721.20
BP: 745.88
745.40
745.84
746.08746.40 747.04 745.96746.88746.68 747.68 745.80746.72
BP: 482.92
482.68
482.68
482.80
481.72 482.96481.32 481.48482.24481.52 481.00 481.56482.40
BP: 860.92
860.88
861.16
861.60
861.20
861.16861.00 859.24 859.56860.28859.16 861.36861.16
BP: 778.68
778.84
777.92 777.16778.92776.04778.36778.56779.20779.44 778.40
BP: 540.68
540.32
540.52540.92
539.12 539.04540.56539.36539.44 540.64539.56540.28539.76
N
m
E
[4
P
_
 121
N
m
E
[4
P
_
N
m
E
[4
P
_
N
m
E
[4
P
_
N
m
E
[4
P
_
N
m
E
[4
P
_
Scan event 1 and 3
Scan event 2 and 3
Scan event 1 and 3***
**
* PG(16:0/16:0)
PE(18:0/18:0)
PG(16:0/0:0)
L--PI
(bovine liver)
PC(16:0/16:0)
SM(d18:1/18:0)
PC(16:0/0:0)
Scant event:
1. High collision energy (46V), 
parent-ion scans of m/z 153 (-
mode). Mass range: 600-900
2. Low collision energy (26V), 
parent-ion scans of m/z 153 (-
mode). Mass range: 400-600
3. Parent-ion scans of m/z 184  
(+ mode). CID energy 47V. 
Mass range: 450-950
 
 
Figure 2. Chromatogram showing the separation of different sphingo- and phospholipids using LC-MS in 
full scan mode as well as multiple parent-ion scanning (scan events) in different time-segment during a 
single chromatographic run. 
 
 
6.3.3. Parent-ion Scanning of Sphingo- and Phospholipids  
 The head groups of sphingo- and phospholipids break down during mass spectrometric 
fragmentation, giving unique product ions which are the characteristics of different lipid 
classes (table 3).  
 The monitoring of sphingo- and phospholipids has been done in parent-ion scanning 
mode on a triple quadrupole mass analyzer, in which full scans of precursor-ions have been 
obtained for the typical product-ions of certain lipid classes. During one chromatographic run, 
different parent-ion scans could be applied during the different time-segments depending on 
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which lipid classes were being eluted (figure 2). However, as baseline chromatographic 
resolution for each single lipid class could not be achieved (see figure 2), multiple parent-ion 
scans had then to be performed on the same time-segment, in which each full parent-ion scan 
had to be conducted sequentially. Moreover, due to the structural heterogeneity of lipid 
species, parent-ions need to be scanned at a wide mass range (the masses of lysolipids range 
between 400 to 600 amu, while the masses of di- or mixed acyl lipids range between 600 to at 
least 1000 amu). Hence, although a quadrupole gains a very efficient duty cycle during single 
ion monitoring of a product ion, efficiency was later severely reduced during multiple parent-
ion scans. This led to a reduced number of scans and ion counts, resulting in decreased 
sensitivity and precision of the less abundant or the less efficiently ionized lipid species. 
Figure 3 shows two mass spectra obtained from parent-ions scans of m/z 184 (identifying 
phosphocholine-containing lipids: PC, LPC, SM; see table 3) from the same plasma sample. 
The spectrum in figure 3A was obtained together with two other multiple parent-ion scans (of 
m/z 153 and m/z 196, see table 3), while the spectrum in figure 3B was obtained with one 
other multiple parent-ion scans (of m/z 153). Figure 3B clearly shows a richer spectrum as 
compared to figure 3A; thus, the more parent-ion scans were conducted, the less information 
(in terms of the number of peaks) was obtained. Therefore, only two different parent-ion 
scans were applied for each time-segment during a single chromatographic run (figure 2): for 
glycerophosholipids or lysophospholipids (parent-ion scans of m/z 153 with high or low 
collision energy, respectively, in a negative mode) and for phosphocholine-containing lipids 
(parent-ion scans of m/z 184 in a positive mode). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Characteristic product ions of different sphingo- and phospholipid classes 
Lipid class Detection Product-
ion (m/z) 
Fragment structure (28) Optimal collision 
energy  at 0.5 
mTorr* (V) 
Glycerophospholipids: 
PG (or lyso-PG) [M]- 44 (or 34) 
PE (or lyso-PE) [M-H]- 43 (or 30) 
PA (or lyso-PA) [M]- 38 (or 21) 
PS [M]- 44 
PI [M]- 
153 
 
46 
Other unique fragmentation: 
PE (or lyso-PE) [M-H]- 196 
 
 
 
 
 
 
 
 
39 (or 23) 
PI [M]- 241 
 
 
 
 
 
 
 
 
45 
Phosphocholine-containing lipids: 
PC (or lyso-PC) [M+H]+ 35 (or 21) 
SM [M+H]+ 
184 
 
 
 
 
 
 
27 
 
 
 
 
 
 
 
 
 
 
 123
 124
450 500 550 600 650 700 750 800 850 900 950 1000
m/z
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
22000
24000
In
te
ns
ity
757.88
785.96
702.96495.88 806.88
519.72 730.24 835.92455.96 878.40696.04524.60 591.84 902.04 991.32943.08629.96 664.64
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p [ ]
Figure 3. Mass spectra of phosphocholine-containing lipids (parent-ion spectra of m/z 184) from the same 
plasma samples but obtained using different number of scan events. A: 3 scant events (parent-ion scans of 
m/z 184, 153 and 196). B: 2 scant events (parent-ion scans of m/z 184 and 153). 
 
 
Since full parent-ion scans were conducted on a wide mass range, the scan time 
affected the quality of the spectra acquired. Figure 4 shows spectra of PG(16:0/16:0) and 
PG(18:0/0:0) standards obtained with 0.2 s scan time (A, C) and 1 s scan time (B, D) for the 
same mass range. Thus a faster scan time increases the number of scans but decreases the 
mass accuracy and isotopic resolution which then can lead to a false identification of the lipid 
species. 
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Figure 4. Parent-ion spectra of PG(16:0/16:0), m/z 721.2 (A, B) , and PG(18:0/0:0), m/z 511.2 (C, D), 
obtained with 0.2 s (A, C) and 1 s (B, D) scan time. The longer scan time improved the mass accuracy and 
isotopic resolution (C, D). 
 
 
6.3.4. Sensitivity and Reproducibility of the Method 
 Accurate quantification of the different lipid species tends to be difficult due to still 
many limitations on the methods developed for lipid profiling (29-30). Hence, reports on 
sphingo- and phospholipid endogenous levels are based on quantification of the total amount 
of a lipid class instead of each lipid species. Moreover, different fatty-acid chain structures 
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within one lipid class already showed different ionization efficiencies (31). Hence, it is 
difficult to determine the sensitivity needed to be able to reliably quantify a certain 
endogenous lipid species. Table 4 gives an indication of the sensitivity and reproducibility 
obtained for different lipid classes, based on investigation of their IS. The endogenous lipid 
species, however, might behave differently due to the difference in fatty-acid structures and 
the presence of different co-eluting lipids from different matrices. As shown in table 4, 
relative signal intensities could be measured with better reproducibility than absolute 
intensities. The higher relative signal intensity improved the reproducibility of the analysis, as 
shown by the relative standard deviation (RSD) of the relative intensities of different lipids in 
each scan event.  
 Table 4 also shows big differences in the ionization efficiencies of different lipid 
classes. Some classes (especially PG and lyso-PA) consistently appeared as the base peaks in 
the particular scan event. Other lipid classes co-eluted with these lipids might undergo ion 
suppression; hence their true abundance in biological samples might be undetermined.  
 
 
Table 4. Reproducibility of lipid standards, expressed as relative standard deviation (RSD) of the peak 
intensities and relative intensities of the parent ions. Relative intensity is the intensity of a parent ion as 
compared to the base peak (100%) of a particular scan event. 
Intensity (arb) Relative intensity (%) Scan 
event* 
Internal 
standard 
Exact   
mass 
Concentration 
(nM) mean ± SD RSD mean ± SD  RSD 
PG(17:0/17:0) 749.533 3.34 2’480 ± 207 8.3% 100.0 ± 0.0 0.0% 1 
(1st) PE(17:0/17:0) 719.547 6.95 584 ± 60 10.2% 24.3 ± 1.5 6.3% 
PA(17:0/0:0) 423.251 5.91 5’390 ± 1’041 19.2% 100.0 ± 0.0 0.0% 
PG(17:1/0:0) 495.272 4.39 1’392 ± 207 14.9% 26.0 ± 2.0 7.7% 
2 
PE(17:1/0:0) 465.286 8.32 807 ± 60 7.5% 17.3 ± 1.2 6.7% 
PI(12:0/13:0) 693.376 3.75 806 ± 98 12.2% 100.0 ± 0.0 0.0% 
PS(17:0/17:0) 762.528 6.56 367 ± 13 3.5% 49.0 ± 1.4 2.9% 
1 
(2nd) 
PA(17:0/17:0) 675.496 7.40 267 ± 26 9.8% 36.0 ± 3.5 9.6% 
PC(17:0/17:0) 761.593 6.57 93’200 ± 10’022 10.8% 100.0 ± 0.0 0.0% 
SM(d18:1/12:0) 646.505 7.73 56’667 ± 3’400 6.0% 62.7 ± 2.3 3.7% 
3 
PC(17:0/0:0) 509.348 9.82 5’030 ± 511 10.2% 8.7 ± 0.6 6.7% 
* See figure 2 
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6.3.5. Feasibility studies in patients and healthy volunteers 
The developed method has been applied for sphingo- and phospholipid analysis of 3 
patients having stable coronary heart disease as well as in 3 healthy volunteers. About 137 
lipid species from different lipid classes have been identified (figure 6).  
Sphingo- and phospholipids are present ubiquitously and their endogenous levels are 
influenced by many factors including fasting state, daytime and dietary behavior. Some 
differences in the concentrations of each lipid species between patients and controls might be 
caused by interindividual variation, rather than by the disease. Nevertheless, certain diseases 
have been shown to be associated with distinct fatty-acid side-chain structures (32). Hence, 
comparison of both the total amount of each lipid class and the concentrations of each lipid 
species within a given class needs to be performed in order to search for disease-related 
differences. The developed method has allowed the measurement of not only the total 
endogenous level of different lipid classes, but also each concentration of the lipid species, 
thus allowing lipid pattern comparisons between patients and controls. 
Multivariate analysis is clearly needed to reveal which lipid species or lipid classes 
that are consistently different between patients and controls. At present, the number of 
samples presented here is too small to be subjected to multivariate analysis. Moreover, the 
resolution of the data needs to be improved to maximize the differences between data clusters, 
for example by employing accurate mass measurement and incorporating retention time 
information. Furthermore, well-matched controls as well as stricter exclusion criteria for 
patients are needed to limit any difference being caused by non-disease related variation and 
for a better interpretation of the results.  
Due to the fact that different fatty-acid chain structures within one lipid class has 
different ionization efficiencies (31) and that non-endogenous, odd fatty-acid chains, lipid 
internal standards have been used in this method, the analysis of sphingo- and phospholipids 
has been only semi-quantitative. Thus, the method provided a screening of the candidate 
lipids that potentially made the difference between patients and controls. These candidate 
lipids need to be further analysed, by identifying their distinct molecular structures (from their 
product-ion spectra in the negative mode) and measuring their absolute concentrations, so that 
they can be later evaluated in multiple clinical studies. 
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Figure 6. Different patterns of sphingo- and phospholipids in patients with stable coronary heart disease 
and healthy individuals. 
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6.4. Conclusions 
An LC-MS/MS method combining normal phase HPLC separation and multiple 
parent-ion scanning on a triple quadrupole mass analyzer has been developed. The method 
allowed the analysis of both the total endogenous amount of lipids within the same class as 
well as the concentration of each lipid species within a given class. The method was applied 
in a feasibility study in patients having stable coronary heart diseases and lipid species from 7 
different lipid classes (SM, PG, PE, PA, PI, PS and PC) have been semi-quantified. 
Improvements of the method are still needed before the method can be applied to large-scale 
clinical studies. For example: automation of the data processing (lipid identification and semi-
quantification) as well as multivariate data analyses. The method provided a screening of 
candidate lipids potential for further evaluation by more targeted, quantitative analysis. 
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7.   GENERAL DISCUSSION AND OUTLOOK 
 
7.1. General Discussion 
The project has emerged from the need to find markers that can improve the reliability 
of cardiovascular disease (CVD) prevention. As described in the “Introduction”, the current 
strategies for stratifying patients at risk for CVD have high false positive rates. For instance, 
the risk prediction from the Munster Heart Study (PROCAM) gives false-positive rates of 68 
and 86% for high and intermediate risks, respectively (1). This means that, for example, out 
of 100 individuals who are diagnosed as having high risk for CVD, 68 persons receive 
aggressive medications to lower their LDL-cholesterol and blood pressure, while they actually 
will not develop CVD. Novel biomarkers are therefore needed to optimize the cost-benefit 
relationship of preventive measures. Moreover, they give a better understanding on the 
pathophysiology of the disease, leading to better therapeutic interventions in different stages 
of CVD progression. 
Decades of research have revealed that HDL plays an important role in the 
development of atherosclerosis, the major contributor for CVD (2-4). The cardioprotective 
effect of HDL has been mainly attributed to its ability to limit cholesterol accumulation in 
peripheral cells via reverse cholesterol transport (4). Secretion and plasma transport of 27-
hydroxycholesterol (27OHC), an oxidized metabolite of cholesterol, has been proposed as an 
alternative route in the situations of disturbed HDL-dependent reverse cholesterol transport 
(5-7). However, as has been shown previously, about 50% of plasma 27OHC in 
normolipidemic population is actually carried by HDL (8). As the beneficial effects of HDL 
on the cardiovascular system are not limited to its role in reverse cholesterol transport, but 
include anti-inflammation, anti-oxidative and cytoprotective as well, other candidate 
biomarkers have also emerged, for example sphingosine-1-phosphate (S1P). Little is known 
on the determinants of S1P levels in plasma. However, S1P has been suggested as the 
component responsible for many anti-inflammatory and cytoprotective effects of HDL (9-12).  
Atherosclerosis is a multifactorial disease whose progression is determined by many 
risk factors such as heredity and environment. Thus, our strategy was analyzing the candidate 
biomarkers in patients having monogenic disorders affecting their HDL metabolism together 
with their unaffected family members as controls, as well as in genetic animal models with 
knock-outs of the same genes. For this purpose, a very sensitive LC-MS method with an 
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atmospheric pressure photoionization (APPI) interface has been developed and validated for 
quantifying 27OHC in plasma and the HDL fraction. The method was more sensitive than the 
published LC-APCI-MS or GC-MS methods; enabling us to analyze as little as 15 L sample 
volume with lower a limit of quantification (LLOQ) of 40 ng/mL or 4.9 pmol on column. 
At a first glance, 27OHC in humans and mice with monogenic disorders of HDL 
genes seemed to behave similarly as cholesterol, prompting us to question whether measuring 
27OHC is not just a laborious way to obtain the same information as with cholesterol 
measurements. However, normalization of HDL-27OHC levels for HDL-cholesterol levels 
revealed at least one interesting exception, which was consistent in both genders and gene-
dosage dependent, namely mutations in lecithin:cholesterol acyl transferase (LCAT), the 
enzyme responsible for cholesterol esterification and its packaging into HDL. Our 
observational study suggested that 27OHC is more sensitive to reduced LCAT activity than 
cholesterol. 
The analysis of S1P in patients with monogenic disorders of HDL metabolism showed 
an interesting feature: the S1P concentration was reduced in patients having HDL deficiency, 
while it was not elevated in patients with high HDL-cholesterol levels. Further investigations 
by stratifying our data and additional experiments indicated the existence of a threshold HDL 
level which limited the concentration of S1P in plasma. Since some of the atheroprotective 
effects of HDL are exerted by S1P, this threshold concentration could be the HDL level 
needed for atheroprotection. This might answer to the current controversial data which shows 
that increasing HDL-cholesterol level (as targeted by novel HDL-modifying therapies) does 
not always prevent cardiovascular events (13-14). 
As yet, only total plasma concentrations of S1P have been investigated for their 
association with CVD. At a first glance, there seems to be contrary findings as S1P plasma 
levels have been shown in one study to increase with the degree of arterial stenosis (15), 
while another much smaller study has shown that S1P plasma levels were lowered in patients 
with myocardial infarction (16). It may however be more important to investigate the 
association of coronary artery disease with HDL-S1P, rather than with total S1P plasma 
concentrations, also because HDL-associated S1P rather than total-S1P appears to exert 
cardioprotective effects (9, 11-12). 
Because multiple lipid classes and species have been shown to be involved in the 
pathogenesis of atherosclerosis, profiling of lipids may reveal additional relevant risk factors. 
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Therefore, a sphingo- and phospholipid profiling project has been started in our institute, in 
which a method has been developed using a combination of on-line normal phase HPLC 
separation and multiple parent-ion scanning on a triple quadrupole mass spectrometer. 
Feasibility has been shown by applying the method for analyzing plasma samples of patients 
with stable coronary heart diseases. Automation of the data mining and lipid identification is 
still a problem that hinders the analysis of larger numbers of samples.  
As has been described in the “Introduction”, different techniques exist for the profiling 
of lipids, in which either parent-ion or neutral-loss scan experiments is one of the most used 
approaches to selectively determine lipid classes. Parent-ion or neutral-loss scans on a triple 
quadrupole mass spectrometer has been usually employed with direct infusion and intra-
source separation (17-18). This approach has been applied for comparative profiling of 
specific sphingo- or phospholipid classes in biological samples (19-21). To minimize ion 
suppression effects as well as to help resolving some isobaric species, chromatographic 
separation is better employed prior to the mass spectrometric analysis. An improvement in the 
separation of different lipids has been shown for example by Houjou et al, who utilized an 
off-line two dimensional separation of normal and reverse phase HPLC (22).  
A few publications have shown the application of lipid profiling to investigate the 
lipid changes in hypertensive and high HDL-cholesterol patients (23-25). One of the most 
recent studies was reported by the group of Oresic et al, who analyzed the lipid composition 
of HDL from well characterized high and low HDL-cholesterol subjects. The lipid analysis 
was performed using ultra-performance liquid chromatography (UPLC) separation combined 
with multiple parent-ion scans (MPIS) technique on the high resolution high accuracy Q-TOF 
instrument. For the first time, lipid profiling was combined with a dynamic modeling of 
lipoprotein structure to show the spatial re-distribution of lipids within the HDL particles (25).  
Similar to the Indian fable of the “blind men and an elephant”, differential approaches 
are useful to have a more complete picture of the pathophysiology of atherosclerosis. 
Technological developments in mass spectrometry and bioinformatics have made possible to 
analyze hundreds of analytes within a single run. However, several problems still wait to be 
solved; of particular importance is the accurate and reproducible quantification of all 
components detected. A lesson from the more advanced field of proteomics, for example as 
nicely reviewed by Nita-Lazar et al (26), tells us that accuracy, selectivity and sensitivity are 
pivotal for a robust and reliable quantification. The impact is that profiling serves as a pre-
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screening method for a later more targeted, quantitative analysis. Any findings from a 
profiling approach should be treated not as a conclusion, but as a novel hypothesis which then 
should be confirmed by further more specific, well-controlled studies including in vitro and 
animal studies. Decades of merit of the time-consuming targeted analysis should not be 
forgotten. As has been shown in chapter 3 and 4, targeted analysis has led us to describe 
specific roles of the compounds of interest in HDL and cholesterol metabolism.   
 
 
7.2. Outlook: Current Challenges and Next Works 
7.2.1. Targeted Lipid Analysis 
27OHC has been proposed as an alternative to the HDL-dependent reverse cholesterol 
transport pathway. However, our observational studies in patients with monogenic disorders 
of HDL metabolism neither support nor contradict this concept. Changes in plasma and HDL-
27OHC in our dyslipidemic patients do not immediately reflect specific changes in the 
regulation of CYP27, the enzyme responsible for the conversion of cholesterol to 27OHC, in 
macrophages. This is because 27OHC is also generated in other cells, notably in the liver for 
an alternative bile acid biosynthetic pathway (27). Measurement of CYP27 enzyme activity in 
combination with 27OHC levels in plasma will certainly help to understand the regulation of 
27OHC and its role in atherogenesis. Furthermore, due to its physiochemical property, 
27OHC has been postulated to be excreted from cells independently of transporters and 
extracellular acceptors (28-29). This assumption needs to be confirmed by in vitro studies of 
the transport of 27OHC from macrophages, with or without the presence of (lipo)-protein 
acceptors and with specifically expressed transporters or receptors, in order to better interpret 
the results from the analysis of 27OHC concentrations in plasma. 
A previous in vitro study by Bjorkhem et al has shown that 27OHC is actually not the 
end product of the CYP27 enzyme (6). It is further oxidized into its carboxylic acid form (3-
hydroxy-5-cholestenoic acid), which is even more hydrophilic and might be more easily 
transported into the blood circulation than its precursors (27OHC and cholesterol). Since 
cholesterol, 27OHC and 3-hydroxy-5-cholestenoic acid altogether compete for the same 
enzyme and are all transported into the circulation, measuring 3-hydroxy-5-cholestenoic acid 
concentrations in plasma may characterize dyslipidemic patients. Moreover, as 27OHC also 
contributes to the de novo bile acid biosynthesis as an alternative precursor, it is also 
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important to combine the measurement of 27OHC with the analysis of bile acids and their 
classical precursors (7-hyxdroxy-4-cholesten-3-one). 
 Our data suggested a threshold HDL level which limits the plasma concentration of 
S1P. This may be due to the fact that S1P is transported by specific HDL subclasses or 
constituents, which are critically lowered in patients with HDL deficiency, but not 
pronouncedly increased in patients having elevated HDL-cholesterol. For example, the minor 
HDL protein constituents, apolipoprotein M (apoM), has been suggested to act as a lipocalin 
(a family of diverse proteins with typical crystal structures which transport small hydrophobic 
molecules) which binds to S1P on 1:1 molar basis (30). Since apoM has similarly low plasma 
concentrations like S1P, this may explain the limited abundance of S1P in HDL. Another 
publication has reported that the S1P content in HDL is elevated in parallel with increasing 
HDL density such that S1P is enriched in the HDL3 subclass (31). Thus, it will be interesting 
to investigate the molecular determinants of S1P uptake and/or transport by specific HDL 
subclasses. 
 
 
7.2.2. Lipid Profiling 
 At present, the actual application of our sphingo- and phospholipid profiling method is 
still laborious and time-consuming, particularly at the data mining step. The development of 
software enabling to automatically process the characterization and semi-quantification of the 
detected lipid species will tremendously help in analyzing a much larger amount of samples. 
To the best of our knowledge, a software package which can help us completely in all our 
data mining steps currently does not exist publicly and most research groups develop their 
own home-made software specific for their types of experiments.  
 As has been discussed in the “Introduction”, several different types of experiments can 
be done in lipid profiling. Thorough investigations comparing these different analytical 
methods, particularly in terms of sensitivity and reproducibility, will be useful for the 
generation of reliable data required for multivariate data analysis. The choice of suitable 
sample cohorts as well as the developed analytical method(s) should be able to distinguish 
between interindividual variation and changes caused by the disease for a better biological 
interpretation. Finally, any outcome needs to be carefully verified and validated by well-
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designed targeted studies involving in vitro and animal studies as well as epidemiological or 
clinical studies. 
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